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ABSTRACT 
Respiratory syncytial virus (RSV) and influenza are the two most common causes of 
acute lower respiratory tract infections in infants.  Epidemiological data suggest that both severe 
RSV and influenza infections during infancy are associated with long-term pulmonary function 
abnormalities.  
Despite of the severe burdens of RSV and influenza infections in infants, no efficacious 
vaccines are available for RSV and the current vaccine strategy for influenza is inconvenient due 
to the fact that vaccines are made annually based on the prediction of circulating strains in the 
next season.  New strategies in vaccine development have been slow to arrive partly due to the 
fact that pathogenesis of RSV and influenza, especially in infants, is not well understood; and 
this is further complicated by the fact that most researchers use adult animal models to study 
immunopathology observed in human infants.   
To better model the infections of these two viruses in infants, we established neonatal 
mouse models for RSV and influenza infections.  In our neonatal mouse model, both RSV and 
influenza infections led to long-term airway hyperreactivity associated with persistent pulmonary 
inflammation.  An inchoate CD8+ T cell response was found to play a significant role in the 
pathogenesis of neonatal influenza infection; while a Th2 (IL-4-producing CD4+ T helper cell)-
biased immune response was responsible for the pathogenesis of neonatal RSV infection and led 
to Th2-skewed secondary responses in adult mice originally infected as neonates.   
In an effort to seek a better vaccine strategy for RSV infection, we used antisense 
oligonucleotides (ASO) against IL-4 receptor α (IL-4Rα) to modulate the T cell responses at the 
time of primary RSV infection.  Upon reinfection with RSV, IL-4Rα ASO treated mice were 
completely protected from airway hyperreactivity.  This finding suggested that there was a 
vii 
delicate balance between Th1 (IFN-γ-producing CD4+ T helper cell) and Th2 cell responses and 
that only a slight push in one direction (i.e., Th1) had a tremendous impact on subsequent 
diseases.  Our data indicate that modulation of the immune responses to RSV during infantile 
infection may be of significant benefit to infants and that IL-4Rα may be part of a viable vaccine 
strategy. 
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CHAPTER ONE:  
GENERAL INTRODUCTION 
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Infectious Diseases 
Infectious diseases are a significant cause of morbidity and mortality worldwide and are 
responsible for nearly 15 million deaths per year, according to the Centers for Disease Control 
and Prevention (CDC; http://www.cdc.gov/ncidod/EID/vol11no04/04-1167.htm).  Of all 
infectious diseases, respiratory infections are the number one cause of mortality, accounting for 
nearly 4 million annual deaths (Morens et al., 2004).  Of all respiratory infections, including 
bacterial, viral, fungal, and protozoal infections (Lednicky and Rayner, 2006), viral infection, 
with variable rates of morbidity and mortality, is the most frequently diagnosed (Denny, 1995).  
Respiratory viral pathogens include rhinoviruses, influenza viruses, adenoviruses, parainfluenza 
viruses, respiratory syncytial viruses (RSV), human metapneumoviruses, and coronaviruses 
(Denny, 1995).  Despite the fact that respiratory viruses usually lead to mild diseases in healthy 
children and adults, infants, elder adults, and immunocompromised individuals have a higher 
risk of developing severe lower respiratory tract infections (LRTIs) (Lee and Barton, 2007).  
RSV and influenza infections are the most common causes of severe respiratory distress and 
hospitalization of children less than five years of age (Carbonell-Estrany et al., 2004; Fiore et al., 
2007). 
Respiratory Syncytial Virus 
The Virus 
RSV is an enveloped virus with a negative-sense, single-stranded RNA genome of ten 
genes, which code for eleven proteins.  There are two serotypes, A and B, which co-circulate in 
the human population; natural non-human reservoirs for RSV do not exist (Anderson et al., 
1985).  Serotype A is usually more virulent than serotype B (Walsh et al., 1997).  Three 
glycoproteins — F (fusion), G (attachment), and SH (small hydrophobic) proteins — reside on 
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the lipid envelope.  The M (matrix) protein consists of the matrix layer underneath the lipid 
envelop.  The 15.2 kb RNA genome is associated with three proteins: the N (nucleocapsid), P 
(phosphoprotein), and L (large protein).  These three proteins, together with two other proteins 
named M2-1 and M2-2, play essential roles in genome replication and transcription.  Two 
nonstructural proteins (NS1 and NS2) are important in modulating host responses to the 
infection.  Specifically, they are thought to inhibit interferon responses within the infected cells 
(Collins and Graham, 2008; Easton et al., 2004).   
Pathogenesis 
The RSV virus is usually transmitted by direct contact with secretions or aerosols 
produced by a sneeze or cough.  The virus replicates in the nasopharynx with an incubation time 
of about four days before symptoms appear.  Symptoms include cough, low-grade fever, 
rhinorrhea, and pharyngitis (Schwartz, 1995).  RSV infects people of all ages.  In most cases, 
only mild upper respiratory tract infection occurs, and this resolves in four to seven days (Kuzel 
and Clutter, 1993).  Disease is more severe in infants, and about 25 to 40 % of infected infants 
develop LRTIs including bronchiolitis and/or pneumonia with 0.5 to 4.4 % requiring 
hospitalization (CDC; http://www.cdc.gov/ncidod/dvrd/revb/respiratory/rsvfeat.htm). 
Once the virus enters the airway, it attaches via the G protein to ciliated and non-ciliated 
epithelial cells.  The G protein contains heparin-binding domains, which interact with 
glycosaminoglycans (Feldman et al., 1999), and a CX3C motif, which binds to CX3CR1 (Tripp 
et al., 2001).  The beating cilia on ciliated epithelial cells help spread RSV to the lower part of 
the respiratory tract, where type I pneumocytes become the primary target cells.  The cytopathic 
effects from the virus itself or from inflammatory cells result in sloughing of epithelial cells in 
the airway.  Inflammatory cells, such as neutrophils, monocytes, and lymphocytes, are recruited 
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to the airways, arterioles, and lung parenchyma.  Some inflammatory cells also penetrate the 
smooth muscle and epithelial cells, reaching the airway lumen (Johnson et al., 2007).  Necrotic 
epithelial cells, inflammatory cells, mucus, fibrin, and excessive liquid in the airways induce 
airway obstruction and increased airways resistance.  Airway obstruction is a hallmark of RSV 
bronchiolitis (Peebles and Graham, 2005). 
Prevention and Treatment 
Despite intense studies of RSV, there are still no efficient antiviral drugs or vaccines.  
Two antibodies to RSV are currently approved for RSV prophylaxis: RSV-IGIV (RespiGam) 
and palivizumab (Synagis).  The use of RSV-IGIV has been largely replaced by palivizumab 
since palivizumab’s approval in 1998 (Barton et al., 2001); and palivizumab is only 
recommended for use in high-risk populations, including children less than two years old with 
chronic lung disease or congenital heart disease and preterm infants born at 35 weeks or less 
gestation (Feltes et al., 2003; Meissner and Long, 2003).  Ribavirin is the only available antiviral 
drug for RSV infection.  However, the efficacy of ribavirin in combating RSV infection is 
controversial (Randolph and Wang, 1996; Ventre and Randolph, 2007).  In clinical practice, 
various supportive therapies are used, including such interventions as nasopharyngeal suctioning 
and ventilation or diverse reagents, such as oxygen, heliox (a combination of helium and 
oxygen), bronchodilators, epinephrine, corticosteroids, surfactants, nitric oxide, recombinant 
human DNase I, and antibiotics(Chidgey and Broadley, 2005).  Each is prescribed to reduce the 
severity of the disease based on one or more aspects of the pathogenesis of RSV bronchiolitis; 
however, none of them cures RSV.   
Vaccine development for RSV has been hampered largely by the tragedy which occurred 
in the 1960s with a formalin-inactivated viral vaccine.  The vaccine was well tolerated and high 
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levels of neutralizing antibodies were found in the serum during the acute (active infection) 
phase of illness.  However, RSV-vaccinated infants became seriously ill upon subsequent 
infection with community-acquired RSV, and 80% of the vaccinated infants required 
hospitalization for bronchiolitis and/or pneumonia.  The severity of illness was inversely 
correlated with age, and histology examinations at lung autopsies showed extensive 
inflammation consisting of mononuclear cells and eosinophils within the peribronchiolar area 
(Kapikian et al., 1969; Kim et al., 1969). 
Various types of new vaccines have been developed, including live attenuated viruses, 
attenuated temperature-sensitive strains, viral mutants with one or more genes deleted, purified 
RSV surface proteins (usually F proteins), synthetic viral peptides, and plasmid vaccines or 
vaccinia virus vectors expressing F or G proteins (Moore and Peebles, 2006; Venkatesh and 
Weisman, 2006).  All of them have been tested in adult mouse models or chimpanzees, and some 
show a certain level of protection (Venkatesh and Weisman, 2006).  However, to date, no 
vaccines have been approved for use in human beings. 
Influenza 
The Virus 
Influenza is an enveloped virus with a segmented, negative-sense, and single-stranded 
RNA genome.  There are three serotypes of influenza including type A, B, and C.  Unlike type B 
and C, which are essentially restricted to humans, type A can infect a variety of hosts including 
humans, birds, pigs, seals, and horses (Brownlee, 2002).  Influenza C usually causes mild upper 
respiratory tract infections, while influenza A and B are associated with severe respiratory 
diseases and seasonal epidemics (Matsuzaki et al., 2006).  Influenza A also leads to pandemics 
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when major antigenic changes of its surface glycoproteins are introduced.  The research 
presented in this dissertation focused on influenza A virus. 
The RNA genome of influenza A contains eight linear segments encoding 10 proteins.  
Three surface proteins are localized on the host cell membrane-derived envelope: 
haemagglutinin (HA), neuraminidase (NA), and matrix (M2) proteins.  Serological reactivity of 
HA and NA is used to subcategorize influenza A.  In total, sixteen HA and nine NA subtypes 
exist; however, only three HA (H1, H2, and H3) and two NA (N1 and N2) subtypes are currently 
circulating in the human population (Fouchier et al., 2005; Obenauer et al., 2006; Webster et al., 
1992).  Beneath the lipid bilayer of the envelope is the matrix protein (M1).  Inside the matrix, 
the eight RNA genomic segments are associated with nucleoproteins (NP) and with an RNA-
dependent RNA polymerase complex consisting of three proteins, named polymerase basic 
protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase acidic (PA) protein.  Like 
RSV, influenza A also contains two nonstructural proteins: NS1 and NS2.  NS1 enhances the 
translation of viral mRNA (de la Luna et al., 1995; Enami et al., 1994), inhibits nuclear export of 
viral and host mRNA (Qian et al., 1994; Qiu and Krug, 1994), and provides resistance to host 
anti-viral responses (Ludwig et al., 2002; Min and Krug, 2006; Talon et al., 2000; Wang et al., 
2000).  The NS2 protein mediates nuclear export of viral ribonucleoproteins (RNPs) and is also 
called nuclear export protein (NEP) for this reason (O'Neill et al., 1998).   
Pathogenesis 
The influenza virus is transmitted by aerosol or droplets and infects people of all ages.  
Once it enters the respiratory tract, influenza replicates rapidly, with a short incubation time of 
one to four days.  Symptoms of infection in adults and adolescents include fever, chills, headache, 
and signs of upper respiratory tract infection such as dry cough, sore throat, and rhinitis (Cox and 
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Subbarao, 1999).  Infections in mild cases usually resolve three to seven days after illness onset 
(CDC; http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5408a1.htm).  However, as with 
infantile RSV infection, influenza infection in infants is more severe, consisting of pharyngitis, 
tracheobronchitis, and sometimes pneumonia (Taubenberger and Morens, 2008).   
Influenza infects epithelial cells of both the upper and lower respiratory tract and alveolar 
macrophages (Fesq et al., 1994; Guarner et al., 2006; Guarner et al., 2000) via HA proteins 
binding to glycoproteins or glycolipids containing sialic acid on the cell surface.  The binding 
triggers receptor-mediated endocytosis of the virus.  HA further mediates fusion of the viral and 
cellular membrane releasing the viral RNPs into the cytosol.  Multifocal necrosis and 
desquamation of infected epithelial cells in the luminal spaces of the airway are characteristically 
found in the trachea, bronchi, and bronchioles (Milton et al, 1920).  Massive destruction of 
epithelial cells usually occurs, leaving only one layer of basal epithelial cells in larger airways 
and sometimes complete loss of epithelial layers in the bronchioli (Goodpasture, 1919; Milton et 
al, 1920).  Edema and congestion of the submucosa and interstitium are often associated with a 
large amount of neutrophils and mononuclear cell infiltrates.  In the resolution stage of infection, 
regeneration of epithelial cells, which can lead to metaplasia of epithelial cells and interstitial 
fibrosis, occurs in order to reconstruct the destroyed epithelial layer (Taubenberger and Morens, 
2008).   
Prevention and Treatment 
Four antiviral drugs for influenza infection are licensed in the United States; all of them 
have to be administered within 48 hours of illness onset, reduce illness duration by only one to 
two days, and work best as prophylactics (Couch, 2000; Moscona, 2005).  These include two M2 
inhibitors, amantadine (Symmetrel) and rimantadine (Flumadine) (Dolin et al., 1982; Monto et 
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al., 1995), and two NA inhibitors, oseltamivir (Tamiflu) and zanamivir (Relenza) (Moscona, 
2005).  The M2 inhibitors are only effective against type A virus, and strains resistant to M2 
inhibitors develop easily (Bright et al., 2006a; Bright et al., 2006b).  In contrast, the NA 
inhibitors treat both type A and type B viruses, and resistant virus strains are rarely isolated 
(McKimm-Breschkin et al., 2003; Moscona, 2004).  None of these antiviral drugs are approved 
for treatment of infants younger than one year of age (Munoz, 2003). 
Despite the use of antiviral drugs to treat and prevent influenza infection, vaccination is 
still considered to be the most efficacious and safest way to prevent infection.  Due to the 
constant and gradual antigenic change (antigen drift) for both influenza A and B, vaccines are 
developed annually based on the prediction of circulating strains for the next season (Fukuda and 
Kieny, 2006; Ohmit et al., 2006).  There are currently two types of vaccines: live-attenuated and 
trivalent inactivated vaccines (Fukuda and Kieny, 2006; Ohmit et al., 2006).  The CDC 
determines which populations are eligible for vaccination each year, a decision largely 
influenced by the availability of vaccines.  In general, vaccination is recommended for 
individuals between six months and two years of age or older than 65 years of age and for those 
who are immune compromised (Pearson et al., 2006).  No vaccine has been approved for infants 
younger than six months of age. 
Contribution of Host Responses to Pathogenesis 
Age as a Factor of Pathogenesis 
Age has been identified as an independent risk factor for development of severe RSV 
disease (Boyce et al., 2000; Welliver, 2003).  The rate of hospitalization associated with primary 
RSV infection declines as a function of age.  About 4.4% of infants younger than six months of 
age require hospitalization for severe RSV bronchiolitis.  This number decreases to 1.5% in 
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infants between six months and eleven months old and decreases further to 0.4% in the second 
year of life.  Finally, by the third year of life, only 0.1% of infants require hospitalization due to 
RSV infection (Welliver, 2003).   
As with RSV, influenza A infects humans at all ages; however, infants and the elderly 
have the highest hospitalization and mortality rates (Bhat et al., 2005; Brotherton et al., 2004).  
The hospitalization rate for children less than five years old is also comparable to that of the 
elderly (Thompson et al., 2004).  As with RSV, the younger the child, the greater the risk for 
hospitalization, with the highest rate in infants younger than six months (Izurieta et al., 2000; 
Neuzil et al., 2000; O'Brien et al., 2004). 
Neonatal Immunity 
Although, under some circumstances, adultlike immune responses can be elicited in 
neonates (Forsthuber et al., 1996; Ridge et al., 1996; Sarzotti et al., 1996), generally speaking, 
neonatal immune responses do not completely recapitulate adult immune responses (Adkins et 
al., 2004).   
Neonatal B Cell and Antibody Responses.  Fewer B cells respond to the infection and 
those that do are inefficient at antibody production (Adkins et al., 2004).  Specifically, in RSV 
infection, infants younger than six months have lower serum anti-RSV antibodies than older 
children (Welliver et al., 1980).  More importantly, a poor correlation between neutralizing 
ability and the amount of RSV-specific IgA and IgG in nasal secretions and serum is observed in 
infants less than six months old (McIntosh et al., 1978; Murphy et al., 1986).  Weak antibody 
responses are also observed in neonatal influenza infection.  When stimulated in vitro, B cells 
from cord blood produce less anti-influenza antibodies than those from healthy adult blood 
(Yarchoan and Nelson, 1983). 
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Neonatal CD4+ T cell Responses.  The number of neonatal CD4+ T cells responding to 
infections is smaller and the responses of these cells are Th2 biased (Adkins et al., 2004).  CD4+ 
T cells are classified into different categories mainly based on the cytokines that they secrete: 
Th1 (IFN-γ and IL-12 producing), Th2 (IL-4, IL-5, and IL-13 producing), regulatory T (TGF-β 
and/or IL-10 producing), and Th17 cells (IL-17 producing) (Neurath et al., 2002).  Th1 cells are 
usually thought to be protective against intracellular pathogens such as viruses, while Th2 cells 
allow for permissive responses.  Th1 cells promote a cascade of inflammatory responses to clear 
the virus.  Th2 cells stimulate IgE production and the activation and proliferation of eosinophils, 
which are responsible for clearing extracellular pathogens and are inefficient at clearing viruses.  
Particularly, Th2-skewed responses are reported in RSV infections in infants (Aberle et al., 1999; 
Renzi et al., 1999; Roman et al., 1997).  A higher Th2-to-Th1 ratio of cytokine production is 
observed in peripheral blood mononuclear cells (PBMCs) from RSV-infected infants compared 
to non-infected controls (Roman et al., 1997).  
Neonatal CD8+ T cell Responses.  Responses of CD8+ T cells in infants are 
considerably weaker in quantity and quality than in adults (Adkins et al., 2004).  Infants with 
severe influenza and RSV infections have fewer CD8+ T cells and a near absence of effector 
function (i.e., aberrant cytotoxic activity including decreased granzyme production) in the lung 
(Welliver et al., 2007).   
Immunopathogenesis 
A Th2-biased immune response to RSV infection has been proposed to explain 
pathogenesis.  PBMCs from RSV-infected infants produce higher IL-4 and lower IFN-γ levels in 
vitro (i.e., a skewed Th2 response) compared to uninfected controls (Bendelja et al., 2000; 
Roman et al., 1997).  Moreover, severe RSV infection in infancy is associated with development 
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of asthma and abnormal lung function into early adulthood (Korppi et al., 2004; Sigurs et al., 
2000; Sigurs et al., 2005; Stein et al., 1999).  Asthma is a Th2 inflammatory disease and allergic 
asthma involves the production of IgE and eosinophilia.  Although severe RSV infection has 
been linked epidemiologically to asthma development, direct experimental data linking the two 
is scarce.  The Th2-biased immune responses to RSV infection in infancy are thought to be the 
mechanism by which RSV predisposes to allergic asthma.   
In contrast to human epidemiology data, mouse studies have shown that RSV infection 
before allergen sensitization alleviates pulmonary allergic responses, including airway 
hyperresponsiveness, IL-13 production, and eosinophilia (Peebles et al., 2001a; Peebles et al., 
2001b).  In addition, RSV infection alone in adult mice elicits a Th1-dominated response, 
characterized by a high ratio of Th1 to Th2 cells and large amount of IFN-γ in the lungs (Peebles 
et al., 2001b).  Interestingly, all of these studies used adult mice.  Three studies, including our 
own, investigated immune responses to RSV infection as a function of age (Becnel et al., 2005; 
Culley et al., 2002; Dakhama et al., 2005).  In toto, these studies show that primary infection of 
neonatal (zero to seven days of age) mice followed by secondary infection in the same mice after 
they matured into adults (twelve weeks of age) resulted in Th2-biased immunity.  In fact, mice 
originally infected as neonates recruited more IL-4+CD4+ T cells (Th2 cells), while mice 
originally infected as adults recruited more IFN-γ+ CD4+ cells (Th1 cells) (Culley et al., 2002).  
These studies (Culley et al., 2002; Dakhama et al., 2005) and our own (Becnel et al., 2005; You 
et al., 2006) highlight the importance of using neonatal mouse models to understand disease 
pathogenesis in human infants.  
Similarities and dissimilarities exist between RSV and influenza infections.  Like RSV 
infections, severe influenza infections usually occur in the very young (less than six months old), 
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the elderly (more than 65 years old), and the immunocompromised indicating that the lack of 
immunity in these three populations is responsible for disease pathogenesis.  Studies in mouse 
models demonstrate that immune responses play a dual role in the pathogenesis of influenza A 
infection.  Knockout or depletion studies of various T cell subsets demonstrate that immune 
responses are beneficial for clearing the virus, but also correlate with massive inflammation and 
severity of lung tissue damage (La Gruta et al., 2007).  Influenza infection initiates Th1 immune 
responses in adult mice, which are usually thought to be protective in viral infections.  Adoptive 
transfer of Th1 cells decreases pulmonary inflammation, while the administration of Th2 cells 
delays viral clearance and enhances pulmonary pathology (Graham et al., 1994; La Gruta et al., 
2007).  CD8+ T cells eliminate the virus through either direct lysis of infected cells or secretion 
of cytokines that induce antiviral responses (Doherty et al., 1997; Topham et al., 1997).  Absence 
of CD8+ T cells delays viral clearance and recovery from infection (Hou et al., 1992; Taylor and 
Askonas, 1986), and passive administration of influenza-specific CD8+ T cells is protective 
against subsequent challenge (Bender et al., 1992).  Intriguingly, the same responses may cause 
extensive lung tissue damage and exacerbate respiratory distress (Moskophidis and Kioussis, 
1998).  All of these observations, again, were made in adult mice with few studies investigating 
infections in neonatal mice.  In contrast to adult data, studies in human infants showed weakened 
CD4+ and CD8+ T cell responses to both influenza and RSV (Welliver et al., 2007).  While the 
adult mouse is a good model for studying immunopathogenesis of highly virulent strains, such as 
the 1918 Spanish influenza, a neonatal mouse model (zero to seven days of age) is more relevant 
for understanding infections in human infants and for testing vaccines and therapies. 
Summary 
RSV and influenza infections are two of the primary causes of acute respiratory 
infections in infants.  Both have been studied intensely in the past several decades.  To date, no 
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efficacious anti-viral drugs or vaccines exist for combating RSV, and antigenic drift and shift in 
influenza A make vaccine development a challenge — “moving target”.  This is partly because 
the mechanisms of pathogenesis are not well defined in either process, although 
immunopathology has recently been accepted as partly responsible for the pathogenesis of both 
RSV and influenza infections.   
As discussed above, age is an important and independent factor, not only for disease 
severity but also for predicting the immune responses to initial and subsequent infections with 
respiratory viruses.  Surprisingly, we are one of a small number of groups that study the 
pathogenesis of respiratory viruses in age-relevant animal models; seven-day-old mice are 
chosen, since the immunological status of mice at seven days of age is thought to be comparable 
to human infants (Adkins et al., 2004; Culley et al., 2002; Dakhama et al., 2005; You et al., 
2006).  Our programmatic hypothesis is that the outcome of respiratory viral infections in 
neonates is determined by the interplay between the host (i.e., neonatal immunity) and viral 
factors (i.e., RSV versus influenza).  Using different viruses (i.e., RSV and influenza) and mice 
at different ages (i.e., neonates and adults), we will be able to identify these host and viral 
factors.   
The majority of this dissertation research aimed to establish neonatal mouse models for 
RSV and influenza A infections, to demonstrate that the outcome of infection depends on age at 
initial infection; and to show that RSV and influenza infections cause pulmonary distress with 
similarities and dissimilarities via different mechanisms (Chapter 2 and 4, respectively).  More 
importantly, the elucidation of the pathogenesis of viral infections should shed light on possible 
therapies or prevention strategies for disease.  Hence, we started to explore a possible vaccine / 
therapeutic strategy for RSV infection in Chapter 3. 
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Introduction 
Respiratory syncytial virus (RSV) is the most common cause of upper and subsequent 
lower respiratory tract infection in children and the elderly and is most severe in children 
between the ages of 8 and 30 weeks (Matthews et al., 2005).  Severe RSV infection occurs in 1-
2% of the cases and may result in acute bronchiolitis that requires mechanical ventilation (Leader 
and Kohlhase, 2002).  
Several studies have suggested that severe RSV lower respiratory tract infection in 
infancy may induce later development of asthma (McConnochie and Roghmann, 1984; Mok and 
Simpson, 1984; Murray et al., 1992; Noble et al., 1997; Pullan and Hey, 1982; Sims et al., 1978).  
In 2000, Sigur and colleagues reported that RSV infection in infancy, severe enough to require 
hospitalization, was associated with asthma and allergy in children up to age 7 (Sigurs et al., 
2000).  More recently, they reported that the relationship between severe RSV bronchiolitis in 
infancy and later development of asthma and allergy sensitization are still observed in children 
up to age 13 (Sigurs et al., 2005).  In murine models, numerous studies have been carried out and 
controversial results have been reported.  While some studies propose that previous RSV 
infection enhances allergen sensitization and exacerbates asthma, others believe that RSV 
infection in infancy protects against later allergic sensitization (Kalina and Gershwin, 2004).  
This controversy is now thought to arise from the age of initial RSV infection and the different 
protocols used for RSV infection and allergen sensitization and challenge.  In two independent 
experiments, researchers suggested that the timing of primary RSV infection is significant for 
predicting disease outcome.  Culley and colleagues reported that if neonatal mice (1 d or 7 d of 
age) were infected with RSV and rechallenged at 12 wks of age, inflammatory cell recruitment 
was enhanced (including Th2 cells and eosinophils) (Culley et al., 2002).  Their data suggested 
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that neonatal exposure to RSV exacerbated subsequent disease upon rechallenge in the adult 
(Culley et al., 2002).  More recently, Dakhama and colleagues infected 1-wk old or 3-wk old 
mice with RSV, and they found that both primary infections led to increased lung resistance, 
mucus hyperproduction and inflammation along with increased lymphocytes in the lung 
(Dakhama et al., 2005).   Furthermore, they demonstrated that the bronchoalveolar lavage fluid 
(BALF) from mice infected with RSV at 1 wk of age had reduced levels of IFN-γ and elevated 
levels of IL-13 compared to mice initially infected at 3 wks of age.  These data indicated that a 
Th2 polarized response occurred in mice infected with RSV at 1 wk of age, while a Th1-biased 
response occurred in the mice infected with RSV at 3 wks of age.  When rechallenged with RSV 
5 weeks later (i.e., infection at 1 wk and reinfection at 6 wks of age), these mice displayed 
exacerbated disease as indicated by enhanced pulmonary resistance, mucus hyperproduction, 
eosinophilia, and elevated levels of Th2 cytokines.  In contrast, initial infection of mice at 3 wks 
of age resulted in protection upon RSV rechallenge as indicated by the abolished lung resistance 
and enhanced viral clearance at rechallenge (Dakhama et al., 2005).  These experiments indicate 
that age at initial RSV infection influences the subsequent immune and physiologic responses 
upon re-exposure to RSV.   
We hypothesized that neonatal exposure to RSV plays a critical role in the 
pathophysiological response to subsequent allergen exposure and the development of allergic 
asthma.  To investigate whether neonatal exposure to RSV influences airway hyperreactivity 
(AHR), mice were infected with RSV at 1 wk of age.  At 6 wks of age, these mice were then 
sensitized and challenged with ovalbumin (Ova).  Pulmonary function, histopathology, and 
BALF cellularity and cytokine production were examined 24 hours after the last Ova challenge.  
The results were compared to sham infected and/or saline exposed mice and demonstrated that 
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neonatal exposure to RSV resulted in elevated and prolonged AHR, chronic pulmonary 
inflammation, and subepithelial fibrosis in adult mice.  These pathophysiological endpoints were 
most severe when neonatal RSV infection was followed by allergen sensitization and challenge.  
These studies demonstrate the ability of neonatal exposures to chronically alter lung function and 
the importance of preventing RSV exposure during infancy. 
Methods 
The study protocol is outlined in Figure 2.1.  Mice were divided into four groups.  RSS 
mice were infected with RSV and mock sensitized and challenged.  OVA mice were mock 
infected then Ova sensitized and challenged.  ROO mice were infected with RSV and then Ova 
sensitized and challenged.  As the control group, SAL mice were mock infected, mock sensitized 
and challenged.  Data were collected on protocol days 0, 4, 69, and 96. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  Schematic of study protocol and exposure groups.  Neonatal mice (seven days 
of age) were infected with RSV (2 x 105 TCID50/g body weight; RSS, and ROO groups).  On 
protocol days 41 and 55, mice were injected i.p. with ovalbumin complexed to Imject Alum 
(OVA and ROO groups) or with isotonic saline (SAL and RSS groups).  These mice were 
then exposed to aerosolized ovalbumin or saline for 20 minutes on protocol days 65, 66, and 
67.  n=8/group. 
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Mice 
BALB/c breeders were purchased from the Division of Laboratory Animal Medicine 
(School of Veterinary Medicine, Louisiana State University) and seven day old pups were 
obtained by time-mating.  All mice were maintained in ventilated micro-isolator cages housed in 
a specific pathogen-free animal facility.  Sentinel mice within this animal colony were negative 
for antibodies to viral and other known mouse pathogens.  All animal protocols were prepared in 
accordance with the Guide for the Care and Use of Laboratory Animals (National Research 
Council, 1996) and approved by the Institutional Animal Care and Use Committee at Louisiana 
State University. 
Infection of Mice with RSV and Assessment of Viral Titers 
Seven day old mice (protocol day 0; Figure 2.1) were infected intranasally (i.n.) with 2 x 
105 TCID50 RSV / g body weight (RSV A-2, Advanced Biotechnologies Incorporated, Columbia, 
MD) or culture media alone (OVA group).  Four days post-infection, viral titer of whole lung 
homogenates was determined using the TCID50 method of Spearman-Kärber (Karber, 1931; 
Spearman, 1908). 
Ovalbumin Sensitization and Challenge 
Mice were sensitized and challenged with chicken ovalbumin (grade V; Sigma, St. Louis, 
MO) as previously described (Becnel et al., 2005).  Mice (OVA and ROO groups) were 
intraperitoneally (i.p.) injected with 20 µg Ova complexed with 2 mg Imject Alum (Al [OH]3/Mg 
[OH]2; Pierce, Rockford, IL) or Sal (RSS and SAL groups) on protocol days 41 and 55 (Figure 
2.1) and subsequently challenged with aerosolized 1% Ova (in isotonic Sal; OVA and ROO 
groups) or Sal (RSS and SAL groups) using an ultrasonic nebulizer (PariNeb Pro Nebulizer) on 
protocol days 65 to 67 (Figure 2.1). 
 27 
Assessment of Pulmonary Function 
A) Lung resistance in response to methacholine 
On protocol day 69, lung resistance to increasing doses of methacholine (MeCh, Sigma; 
0, 6.25, 12.5, and 25 mg/ml in isotonic saline) was assessed using the forced oscillation 
technique as previously described (Becnel et al., 2005).  Anesthetized animals were 
mechanically ventilated with a tidal volume of 10 ml / kg and a frequency of 2.5 Hz using a 
computer-controlled piston ventilator (FlexiVent, SCIREQ; Montreal, Canada).  Resistance data 
were collected using single compartment model and plotted as the percent change from the 0 
mg/ml MeCh dose.  
B) Airway hyperreactivity in response to methacholine 
Airway hyperresponsiveness to MeCh (Sigma; 0, 6.25, 12.5, 25, and 50 mg/ml in isotonic 
saline) was assessed by whole body plethysmography (Buxco Electronics, Troy, NY and EMKA 
Technologies, Falls Church, VA) as described previously (Becnel et al., 2005).  Mice were 
exposed to aerosolized MeCh for 3 minutes at each dose and enhanced pause (Penh) was 
recorded for 3 minutes and averaged for each dose.  Penh data were plotted as percent change 
from saline per dose. 
Determination of Bronchoalveolar Lavage Fluid Cellularity 
On protocol day 69, BALF was isolated in 1 ml of PBS containing 2% heat-inactivated 
FBS.  Total BAL cellularity was determined with the use of a hemocytometer.  Cytospin slides 
were fixed and stained using the Diff-Quick kit (IMEB, Chicago, IL), and differential cell counts 
by two unbiased observers were obtained using standard morphological criteria to classify 
individual leukocyte populations.  Three mice from each group were used for these analyses, and 
200-300 cells were counted per cytospin preparation.   
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Pulmonary Histopathology 
On protocol day 69, lungs were inflated with 1 ml of 4% paraformaldehyde.  The lungs 
were then excised and fixed in 4% paraformaldehyde for 24 hours at 4°C.  These tissues were 
then embedded in paraffin, cut in 4 µm frontal sections and stained with hematoxylin and eosin 
(H&E), periodic acid-Schiff (PAS) to show mucus production in airway goblet cells, or 
Masson’s trichrome (MT) to indicate airway collagen deposition.  Scores were assigned to these 
histological endpoints by two independent observers and were recorded on a scale of 0-3. 
Cytokine Level in BALF 
IL-2, IL-4, IL-5, IFN-γ, and TNF-α levels in the BALF were examined using the Mouse 
Th1 / Th2 Cytokine Cytometric Bead Array Kit (BD Biosciences, San Diego, CA) as per the 
manufacturer’s instructions.  Data were acquired with a BD FACScan™ flow cytometer.  Data 
analyses were performed using the BD Cytometric Bead Array Software to generate standard 
curves for each cytokine and to determine sample cytokine levels.    IL-13 levels in BALF were 
determined using the Mouse IL-13 ELISA Ready-SET-Go kit (eBioscience, San Diego, CA).  
The sensitivity for each cytokine is as follows: 5.0 pg/ml for IL-2, IL-4, and IL-5; 2.5 pg/ml for 
IFN-γ, 6.3 pg/ml for TNF-α, and 30 pg/ml for IL-13. 
Statistical Analysis 
Data are presented as mean ± SEM and were obtained from experiments with n=8 for 
whole body plethysmography analysis of AHR, n=4-5 for invasive measurements of pulmonary 
mechanics, and n=3 for BALF cellularity, cytokine assays, pulmonary viral titers and histology.  
For AHR, lung resistance and BALF cellularity, differences between groups were evaluated by 
means of two-way ANOVA using GraphPad Prism (Graphpad Software Inc, San Diego, CA).  
Bonferroni post-tests were performed to compare between pairs of groups.  A one-way ANOVA 
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was used to compare the mean cytokine levels among the various groups followed by the Tukey-
Kramer multiple comparison tests for significance between the groups.  This was repeated for 
each individual cytokine.  Differences between means were considered significant when p < 
0.05. 
Results 
Reduced Pulmonary Function Was Observed in Mice Infected with RSV as Neonates 
To determine if neonatal exposure to RSV is sufficient to induce long-term pulmonary 
dysfunction, mice were infected with RSV (2 x 105 TCID / g body weight) at seven days of age 
and then allowed to mature to adults (Figure 2.1).  Four days post-infection, we assessed 
pulmonary viral titers for Sham and RSV infected mice.  As expected, mice from the Sham 
infected groups displayed no evidence of viral replication.  The mean viral titer in the lungs of 
neonatal mice exposed to RSV alone (RSS and ROO) was 2.67 ± 1.29 x 106 TCID50/g lung 
tissue. 
After maturation, subsets of mice were then sensitized (protocol days 41 and 55) and 
challenged (protocol days 65, 66, and 67) with ovalbumin - OVA and ROO groups.  All other 
mice received saline - RSS and SAL groups.  AHR was assessed on protocol days 69 and 96 (2.5 
and 3.5 months after infection).  We observed no significant difference in baseline airway 
resistance between the RSV infected (0.52 ± 0.01 cm H2O·s/ml) or sham infected mice (0.64 ± 
0.06 cm H2O·s/ml).  For ease of comparison among all groups, lung resistance data was 
normalized by plotting the percentage difference from baseline (percent difference = 100 * 
((value-baseline)/baseline).  Lung resistance in response to increasing concentrations of inhaled 
MeCh was significantly greater in RSV infected neonates (RSS; 121.79 ± 10.20 cm H2O·s/ml) 
than control mice (SAL; 89.05 ± 6.51 cm H2O·s/ml) at 25 mg/ml MeCh (1.4 times, p<0.01)  
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Figure 2.2  Airway hyperreactivity in RSV and/or Ova exposed mice.  Mice were infected 
with RSV as neonates (RSS) and exposed to Ova 5 wks later (ROO).  Controls were sham 
infected and exposed to Saline (SAL) or Ova (OVA).  A. Lung resistance of each group is 
plotted as a function of increasing doses of inhaled MeCh, using single compartment model. 
B. Penh is plotted as a function of increasing dose of inhaled MeCh (0 to 50 mg / ml).  Data 
were collected on protocol days 69 (A) or 96 (B), normalized to saline airway responses as 
described in methods, and expressed as mean ± SEM.  n=4-5/group.  ***p< 0.001; **p<0.01. 
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(Figure 2.2.A).  Neonatal RSV infection followed by exposure to Ova (ROO) resulted in the 
highest lung resistance among the four groups (392.50 ± 32.84 cm H2O·s/ml).  This increased 
airway resistance was greater than could be accounted for by Ova exposure alone (OVA; 264.63 
± 23.01 cm H2O·s/ml).  Thus, neonatal exposure to RSV infection appears to predispose adults to 
the development of airway hyperresponsiveness to subsequent allergen exposure. 
To investigate the long-term influence of neonatal exposure to RSV, AHR was assessed 
by whole body plethysmography on protocol day 96 (103 days of age).  Penh data was 
normalized and the percentage difference from baseline was plotted.  Mice in the RSS group 
continued to demonstrate reduced airway function 3 months post-infection as evidenced by a 
significantly increased Penh compared to SAL mice at 25 and 50 mg/ml MeCh (314.30 ± 40.40 
vs 100.00 ± 40.80 at 25 mg/ml; 714.30 ± 101.00 vs 311.10 ± 58.80 at 50 mg/ml; p<0.001 and 
p<0.001, respectively) (Figure 2.2.B).  These data demonstrated that neonatal infection with 
RSV resulted in the development of chronic AHR, and furthermore, that airway function was 
further diminished due to an allergic phenotype.  
Neonatal RSV Infection Predisposes Mice to Chronic Pulmonary Inflammation Indicated 
in BALF Cellularity 
To evaluate the pulmonary immune responses to RSV, BALF was isolated, total cells 
recovered were counted, and the cellular composition of BALF was determined using 
morphological criteria.  RSV and/or Ova exposed mice recruited significantly more leukocytes 
than control mice (SAL group, p< 0.001) (Figure 2.3).  However, there was no significant 
difference in the total number of recovered cells among the RSS, OVA, and ROO groups.  
Interestingly, BALF cellularity was elevated in mice exposed to RSV as neonates (RSS) on 
protocol day 69.  Upon allergen sensitization and challenge, total BALF cellularity was not  
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Figure 2.3  BALF cellularity in RSV and/or Ova exposed mice.  Bronchoalveolar lavage 
fluid was isolated on protocol day 69.  RSV and/or Ova induced significant increase in total 
BAL cellularity.  In mice exposed to RSV as neonates (RSS), this increase correlated with 
elevated levels of macrophages; whereas, in mice exposed to Ova (ROO and Ova), this 
increase correlated to elevation in eosinophil numbers.  Data are expressed as means ± SEM, 
n=3/group.  ***p < 0.001 
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significantly altered compared to RSS although the cell populations were changed.  Neonatal 
RSV infection resulted in a predominantly monocyte/macrophage pulmonary infiltrate and these 
cells seemed to account for the elevation in the total number of recovered cells.  In contrast, Ova 
exposure, in the absence (OVA) or presence of neonatal RSV (ROO) infection, resulted in a 
significant BALF eosinophilia (compared to control SAL group, p<0.001).  Concomitant with 
the observed increase in BALF eosinophil number in the OVA and ROO groups was a decrease 
in BALF macrophage number.   
Cytokine Levels in BALF Is Altered in Mice Exposed to RSV and/or Ova 
Cytokine levels in BALF were examined to study the Th1/Th2 polarization in RSV 
and/or Ova exposed mice.  As shown in Figure 2.4.A, we assayed cytokine levels in BALF five 
hours post-infection, and observed greatly elevated TNF-α (21.4 times, p<0.001) in RSV 
infected neonates.  In addition, Th2 cytokines (IL-4 and IL-5) along with IL-2 were detected in 
BALF of neonatally infected mice whereas no IL-4, IL-5, or IL-2 was detected in control mice 
(SAL group).  TNF-α levels declined by protocol day 69 in mice infected with RSV as neonates, 
but was elevated in RSV infected and Ova exposed mice (ROO group, Figure 2.4.B).  
Intriguingly, IL-13 levels were elevated in RSS mice at protocol day 69 compared to SAL mice 
(p<0.001).  Mice exposed to RSV and Ova (ROO group) showed increased Th2 cytokines (IL-5 
and IL-13) compared to SAL group.  In addition, IL-13 levels in ROO mice were significantly 
elevated compared to the animals exposed to Ova alone (OVA group; p<0.01).  Neonatal 
infection with RSV also resulted in increased levels of TGF-β1 protein in the lungs 4d post-
infection (RSS: 29.8 ± 0.45 ng/g lung tissue) compared to mice exposed to Sal alone (22.1 ± 0.39 
ng/g lung tissue). 
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Enhanced Pulmonary Histopathology in Mice Exposed to RSV and/or Ova 
Airway inflammation, mucus hyperproduction, and collagen deposition in the 
subepithelial reticular layer of the airway were observed in mice exposed to RSV and/or Ova 
(Figure 2.5.A: inflammation; Figure 2.5.B: mucus production; Figure 2.5.C: collagen 
deposition).  Mice exposed to both RSV and Ova demonstrated the largest amount of 
inflammation, mucus production, and collagen deposition (Figure 2.5.D), and this was consistent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4  Cytokine levels in the BALF of mice exposed to RSV and/or Ova.  
Bronchoalveolar lavage fluid was isolated 5 hr post-infection with RSV (A) or on protocol 
day 69 (B).  A. Elevated levels of TNF-α, IL-5, IL-4, and IL-2 were observed as early as 5 
hrs post-infection, although significance over SAL controls was observed only for TNF-α. 
IL-2, IL-4, and IL-5 were below the limit of detection in the SAL mice.  B. IL-13 was 
significantly elevated in RSS mice; while TNF-α, IL-5, and IL-13 were significantly 
enhanced in mice exposed to RSV and Ova (ROO).  IL-13 was below the limit of detection in 
control animals (SAL).  Data are expressed as means ± SEM, n=3/group.  ***p < 0.001, 
**p<0.01, and *p<0.05. 
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with the greatest lung resistance and airway hypersensitivity (Figure 2.2).  In addition, 
tremendous perivascular inflammation was observed in both groups of mice exposed to Ova (i.e., 
OVA and ROO mice; Figure 5A).  Mice infected with RSV as neonates displayed chronic (69d 
post infection) inflammation, mucus production and collagen deposition compared to control 
mice (SAL group), which also correlated to enhanced lung resistance and airway hypersensitivity 
in the RSS group (Figure 2.2).  Increased peribronchial and perivascular collagen deposition and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5  Lung histopathology of mice exposed to RSV and/or Ova.  Lung tissue 
sections were obtained from mice on protocol day 69.  Tissue sections were stained with 
H&E (A), PAS (B), and MT (C).  A. Lung inflammation, B. mucus (purple) hyperproduction, 
and C. collagen (blue) deposition were observed in mice exposed to RSV and/or Ova.  D. 
Scores were assigned to these histological endpoints by two independent observers and were 
recorded on a scale of 0-4.  Increased deposition of peribronchial and perivascular collagen 
was observed in the subepithelial reticular layer of the airways in RSS, OVA and ROO mice.  
In all cases, neonatal RSV infection (RSS) induced persistent lung pathologies including 
increased peribronchial inflammation, mucus production, and subepithelial fibrosis were 
exacerbated by subsequent exposure to allergen (ROO).  n=3/group.  ***p < 0.001, *p<0.05. 
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peribronchial smooth muscle deposition indicated that airway remodeling occurred in mice 
exposed to RSV and/or Ova (Figure 2.5.B), and that neonatal RSV infection alone was sufficient 
to induce airway remodeling. 
Discussion 
In the present study, we have shown that neonatal exposure to RSV alone induced long-
term airway hyperresponsiveness and pulmonary resistance in mice.  This result was correlated 
with peribronchial inflammation, increased BALF cellularity, increased mucus production, and 
airway remodeling.  Elevations in TNF-α and Th2 cytokines (IL-4 and IL-5) were observed in 
BALF immediately following neonatal RSV infection.  Once these mice had matured (protocol 
day 69), only IL-13 remained elevated in the BALF.  Neonatal RSV infection followed by adult 
exposure to allergen resulted in significantly higher lung resistance, along with increased total 
cellularity, eosinophilia, and increased TNF-α and Th2 cytokines (IL-5 and IL-13) in BALF.  In 
addition, TNF-α and IL-13 were significantly higher compared to mice exposed to Ova alone.  
The most severe lung histopathology was observed in mice exposed to both RSV and Ova, as 
indicated by severe peribronchial and perivascular inflammation, mucus production, and 
collagen deposition.  Collectively, these data suggest that neonatal RSV infection influences 
adult immune response to allergen (Ova) and exacerbates allergic pathophysiology in mice long 
after viral titers are no longer detectable. 
In contrast to previously published studies analyzing the effect of RSV infection on 
allergen exposure in adult mice (Peebles et al., 2001), the present study investigated the 
influence of neonatal RSV infection on adult allergen sensitization.  Neonatal infection with 
RSV alone was sufficient to induce long-term pulmonary dysfunction and inflammation.  
Similarly, neonatal infection of brown Norway rats with parainfluenza type 1 (Sendai) virus also 
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led to increases in pulmonary resistance and hyperresponsiveness to methacholine up to 65d after 
infection (Sorkness et al., 1991).  As in our model, persistent airway dysfunction following 
neonatal infection with Sendai virus correlated with increased peribronchial fibrosis and 
pulmonary inflammation (Uhl et al., 1996).  Furthermore, both models (i.e., neonatal RSV 
infection and neonatal Sendai virus infection) resulted in significantly increased mRNA (Uhl et 
al., 1996) and protein levels for TGF-β1.  Although numerous cytokines may contribute to 
airway remodeling, the elevation of TGF-β1, a fibrogenic cytokine, in both neonatal viral 
infection models prior to the development of fibrosis suggests a role this cytokine in the 
regulation of viral-induced airway remodeling observed in neonates.   
More importantly, neonatal infection with RSV predisposed mice to the development of 
enhanced AHR and inflammation after allergen exposure.  In contrast, adult RSV infection prior 
to allergen exposure seemed to assert a “protective” response as evidenced by significantly 
decreased allergen induced pulmonary resistance, tissue eosinophilia, and IL-13 levels (Peebles 
et al., 2000).  Our data presented here and elsewhere (Becnel et al., 2005) extend these findings 
and, more importantly, demonstrate that the age at initial RSV infection also determines whether 
RSV infection will exacerbate or prevent subsequent allergic inflammation.   
A more recent study using neonatal RSV infection followed by subsequent reinfection of 
adults with RSV demonstrated that early RSV infection also exacerbates RSV induced diseases 
in the adult (Dakhama et al., 2005).  Interestingly, if the primary RSV infection occurred at 3 
wks of age, a protective effect upon secondary infection was observed similar to that reported by 
Peebles and colleagues (Peebles et al., 2001).  Dakhama and colleagues further established that 
enhancement of AHR, pulmonary eosinophilia, and mucus hyperproduction during reinfection 
were dependent on IL-13 (Dakhama et al., 2005).  We demonstrated that neonatal RSV infection 
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alone leads to elevated levels of IL-13 in the lung and that exposure to allergen significantly 
increases IL-13 levels over RSV exposure alone.  IL-13 has emerged as a major regulatory 
molecule involved in mucus hyperproduction and allergen induced AHR (Kuperman et al., 2002; 
Taube et al., 2002; Wills-Karp and Chiaramonte, 2003).  It is entirely possible that the long-term 
AHR, pulmonary inflammation, and mucus production observed in our neonatal RSV model is 
due to high levels of IL-13.  In fact, elevated levels of IL-13 were observed in whole lung 
homogenates as early as 5 hours post-infection (data not shown) and were again observed in 
adult lungs on protocol day 69 suggesting that IL-13 is being chronically produced.  Although 
the exact cellular source of IL-13 in this neonatal model of RSV infection is currently unknown, 
previous studies have demonstrated that epithelial cells and/or macrophages infected by RSV are 
a significant source of IL-13 and are capable of producing this cytokine for months after the 
initial infection (Schwarze et al., 2004).  We are currently investigating this possibility.   
In our study, TNF-α was significantly elevated in the BALF shortly after infection with 
RSV.  TNF-α is an important cytokine for innate immune responses and a central regulator of 
inflammatory processes, through binding to distinct membrane receptors, referred to as p55 or 
TNFR1 and p75 or TNFR2 (Peschon et al., 1998).  TNF-α is likely a central mediator of airway 
inflammation and AHR in asthma, regulating inflammatory cell infiltration, locally enhancing 
vascular permeability, and inducing the release of the chemokines.  Ultimately, this will lead to 
chronic inflammation and irreversible airway remodeling.  Recently, depletion studies using 
monoclonal antibody therapy for TNF-α have shown promising effects in viral-specific lung 
immunopathology (Hussell et al., 2001), rheumatoid arthritis (Lovell et al., 2000) and 
inflammatory bowel disease (Bell and Kamm, 2000).  Moreover, a soluble TNF receptor fusion 
protein, etanercept, has proven efficacious in treating juvenile rheumatoid arthritis in patients as 
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young as 4 (Lovell et al., 2000).  In viral models, TNF-α depletion reduced recruitment of 
inflammatory cells, reduced type 1 and type 2 cytokines in BALF, and decreased pulmonary 
pathology without inhibiting viral clearance (Hussell et al., 2001; Rutigliano and Graham, 2004).  
Although the precise mechanism by which TNF-α leads to the pathology in lungs after RSV 
infection remains unknown, our data and these previous studies suggest a key role for TNF-α in 
chronic inflammation in the lung and subsequent airway remodeling associated with asthma.   
Several studies along with our present data have established the correlation of severe RSV 
infection followed by allergen exposure and the development of allergic inflammatory disease 
(i.e., asthma) in mice.  Although the mechanism by which the exposure causes asthma and the 
importance of such exposures in humans need to be further elucidated, our current and 
previously published data (Becnel et al., 2005) demonstrate that the initial age of the RSV 
infection is capable of altering adult pulmonary function and exacerbating pulmonary 
immunopathology when followed by subsequent allergen exposure.  Furthermore, enhanced 
AHR correlated with chronic pulmonary inflammation, upregulation of the Th2 cytokine, IL-13, 
and subepithelial fibrosis of the bronchial airways.  Increases in TNF-α within 5 hours of RSV 
infection in our mouse model also suggest a role for this cytokine in the immunopathology of 
RSV-induced wheeze and asthma development in humans.   
Conclusion 
We have demonstrated that neonatal infection with RSV in mice leads to reduced lung 
function, which is associated with chronic inflammation, increased mucus production, and 
airway remodeling in the lung.  In addition, RSV infection in neonates predisposes the adult to 
develop enhanced airway responses upon allergen exposure.  The upregulation of IL-13 and 
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TNF-α suggests that these cytokines may play a key role in mediating this process and highlights 
the importance of these cytokines as therapeutic targets for RSV induced asthma.  
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CHAPTER THREE: 
PREVENTION OF PULMONARY DYSFUNCTION DURING 
REINFECTION WITH RESPIRATORY SYNCYTIAL VIRUS BY 
ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES TO 
IL-4RALPHA DURING PRIMARY INFECTION 
 44 
Introduction 
Respiratory syncytial virus (RSV) is a common cause of upper and lower respiratory 
infection in humans.  Each year in the United States, RSV causes about 91thousand 
hospitalizations (Anderson et al., 1990) and has an economic impact of about 300 million dollars 
(Openshaw, 2002).  Although the majority of RSV infections result in only mild pulmonary 
diseases, about 25 to 40% of infants develop severe bronchiolitis and/or pneumonia with 0.5 to 
4.4% of these requiring hospitalization (Collins and Graham, 2008; Welliver, 2003).  Severe 
RSV bronchiolitis in infancy adversely affects lung function and respiratory health into 
adulthood (Korppi et al., 2004; Sigurs et al., 2000; Sigurs et al., 2005).   
The pathogenesis of RSV infection is not well understood.  However, data in humans and 
mice support the notion that a Th2-biased immune response develops which is at least partly 
responsible for RSV-induced pulmonary dysfunction.  Th2 and Th1 cells are two subsets of T 
helper cells (CD4+ T cells).  Primary RSV infection in neonatal mice (seven days of age) 
predisposes the response of T helper cells to a Th2-dominant response upon secondary infection.  
This response is characterized by pulmonary eosinophilia and goblet cell hyperplasia (Culley et 
al., 2002; Dakhama et al., 2005).  The mechanisms by which neonatal exposure favors a Th2 
response upon priming and rechallenge with RSV are unclear and are a major obstacle for the 
development of effective pediatric vaccines. 
The first hint to why neonatal exposure usually gives rise to a Th2-biased secondary 
response was presented by Zaghouani’s group (Li et al., 2004).  They showed that although both 
Th1 and Th2 responses are elicited in neonatal mice during primary challenges with allergens, 
secondary responses are dominated by Th2 cells.  Specifically, Th1 cells are selected to undergo 
apoptosis in the secondary response, leaving the Th2 cells and thus a Th2-dominated secondary 
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response.  Apoptosis correlates with increased expression of the IL-13 receptor α 1 (IL-13Rα1) 
subunit.  Furthermore, blockade of either the IL-13Rα1 or IL-4 receptor α  (IL-4Rα) subunit 
during priming with antigen blocks apoptosis and restores Th1 recall responses.  This finding 
provides a possible mechanism for Th2-biased secondary responses and emphasizes the 
importance of IL-4 and IL-13 signaling in the development of Th2 recall responses.   
IL-4 is the major cytokine inducing Th2 cell differentiation and, therefore, an important 
regulator in Th2-biased immunopathogenesis of neonatal RSV infection.  IL-13, an important 
Th2 cytokine, stimulates the differentiation of goblet cells (Tyner et al., 2006) and has been 
shown to mediate the airway hyperresponsiveness caused by both primary (Tekkanat et al., 2001; 
You et al., 2006) and secondary RSV infections in mice (Dakhama et al., 2005).  Both IL-4 and 
IL-13 signal through receptors which share a common subunit, IL-4Rα.  The type I IL-4 receptor 
is composed of the IL-4Rα and common γc chains and binds only to IL-4.  The type II IL-4 
receptor is a heterodimer consisting of the IL-4Rα and IL-13Rα1 chains and binds to both IL-4 
and IL-13.  Besides the type II receptor, another IL-13 receptor exists, which is thought to be a 
decoy receptor for negative regulation of IL-13 (Chatila, 2004).   
We hypothesized that local inhibition of IL-4Rα expression would prevent the Th2 
dominated secondary responses to RSV infection and improve pulmonary function in adult mice 
originally infected with RSV as neonates.  To reduce IL-4Rα expression in the lung, antisense 
oligonucleotides (ASO) against IL-4Rα were administered intranasally. 
Methods 
Mice 
BALB/c mice were purchased from Harlan Sprague Dawley, Inc and housed in a 
specific-pathogen-free facility located in the Animal Care Facility at the Louisiana State 
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University Health Sciences Center.  Breeders were time-mated, and pups born on the same date 
were randomized and grouped according to the study design.  All animal protocols used were in 
accordance with the Guide for the Care and Use of Laboratory Animals (National Research 
Council, 1996) and were approved by the Institutional Animal Care and Use Committee. 
Administration of Oligonucleotides 
The antisense oligonucleotides against IL-4Rα and the non-specific seven-base mismatch 
oligonucleotides (MM) were provided by Isis Pharmaceuticals, Inc.  Both oligonucleotides were 
20 bases in length with 2’-O-methoxyethylribose modification on bases 1 to 5 and 16 to 20.  The 
sequences of the ASO and MM are shown below; the mismatched bases are presented in lower 
case (Karras et al., 2007).   
ASO: 5’-CCGCTGTTCTCAGGTGACAT-3’ 
MM: 5’-CCaCTcaTCaCtGcTGACtT-3’ 
The ASO and MM were suspended in sterile saline and administered intranasally (i.n.) to 
mouse pups at a dose of 500 µg/kg body weight.  Control pups (i.e., SHAM, SAL, RSV, and RR) 
received sterile saline.  
Inoculation and Titer Determination of RSV 
The original RSV stock was purchased from Advanced Biotechnologies, Inc, propagated 
in our laboratory, and stored in aliquots at -80 ºC.  Seven-day-old pups were infected intranasally 
with RSV (2x105 TCID50/gram body weight) in 10 µl of Dulbecco's modified Eagle's medium 
(DMEM) containing 2% heat-inactivated fetal bovine serum (FBS).  Similarly, adult mice were 
infected with RSV (2x105 TCID50/gram body weight) in 50 µl of the same media.  SHAM mice 
received media alone. 
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To determine lung viral load, lungs were isolated, placed in media, and stored at -80 ºC 
until processing.  To process, lungs were homogenized, cellular debris was pelleted by 
centrifugation, and clarified supernatants were used to infect 96-well plates of Vero cells (ATCC 
# CCL-81).  TCID50 were calculated using the method of Spearman-Kärber (Karber, 1931; 
Spearman, 1908).   
Experimental Design 
The experimental design is outlined in Figure 3.1.  Mice were treated with IL-4Rα ASO 
i.n. on protocol days -5, -3, -1, and 1 and infected with RSV on protocol day 0 (seven days of 
age).  Expression of IL-4Rα on various lung cells was determined on protocol day 0 prior to 
RSV infection.  Three groups were included in the expression study (not shown in Figure 3.1): 
SAL (treated with saline), ASO (treated with IL-4Rα ASO), and MM (treated with MM).  Viral 
titers and T cell populations during primary infection were determined on protocol days 4 and 6, 
respectively.  After the treated mice matured (six weeks of age), all groups except SHAM were 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  Experimental design.  Four groups were included in the study: one experimental 
group (ARR) and three control groups (SHAM, RR, and MRR).  For the ARR group, pups 
received IL-4Rα ASO i.n. on protocol days -5, -3, -1, and 1 and were infected with RSV on 
protocol day 0.  Mice were allowed to mature to six weeks of age and were reinfected with 
RSV.  SHAM mice received saline and media instead of oligonucleotides and RSV.  RR mice 
were treated with saline and infected with RSV.  MRR mice received MM and RSV.  Various 
analyses were performed at different time points, as indicated, including expression of IL-
4Rα, T cell populations (T pop), lung viral titers and histology, pulmonary function (PFT), 
and bronchoalveolar lavage fluid (BALF) cellularity and cytokine levels. 
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reinfected with RSV.  Six days post-infection (dpi), various endpoints — including pulmonary 
function, bronchoalveolar lavage fluid (BALF) cellularity and cytokine levels, and T cell 
populations — were determined.  Four groups were included in these studies (Figure 3.1): 
SHAM (treated with vehicles only, saline and media as appropriate); RR (treated with saline and 
infected with RSV); MRR (treated with MM and infected with RSV); and ARR (treated with IL-
4Rα ASO and infected with RSV). 
Cell Surface Antigen and Intracellular Cytokine Staining 
To determine the expression level of IL-4Rα on various lung cells, single lung cell 
suspensions were prepared in RPMI-1640 supplemented with 2% heat-inactivated FBS, 100 
U/ml penicillin and 100 mg/ml streptomycin (HyClone), and then split into two subsets.  One 
subset was stained with antibodies to IL-4Rα and to CD4 and CD8 to identify T cell subsets.  
The other was stained with antibodies to IL-4Rα and to E-cadherin, CD45, CD11c, and CD11b 
to identify airway epithelial cells (E-cadherin+ CD11b- CD45-) and myeloid dendritic cells 
(mDCs; CD11c+ CD11b+). 
To determine the T cell subpopulations, single lung cell suspensions were isolated in 
RPMI-1640 media supplemented with 2% heat-inactivated FBS, 100 U/ml penicillin and 100 
mg/ml streptomycin (HyClone), and stimulated at 37 ºC in the same media that was additionally 
fortified with 5 ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma), 500 ng/ml ionomycin 
(Sigma), and a protein transport inhibitor (1µl/106 cells; GolgiPlug, BD Biosciences).  After 
stimulation for five hours, cells were washed and stained with antibodies to surface antigens 
(CD4 and CD8); and then fixed, permeabilized, and stained with antibodies to intracellular 
cytokines (IFN-γ and IL-4) to identify T cell subsets.   
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After staining, cells were washed and fixed in a paraformaldehyde-based fixative (BD 
Stabilizing Fixative; BD Biosciences).  Staining profiles of these cells were acquired on an 
LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (Version 7.2.2 for 
Windows, Tree Star, Inc).  Antibodies, including PerCP-CD4 (RM4-5), Alexa Fluor 488-CD8a 
(53-6.7), FITC-E-cadherin (36/E-cadherin) and PE-IL-4Rα (mIL4R-M1) were purchased from 
BD Biosciences.  Others, including PE-Cy7-CD11c (N418), APC-CD11b (M1/70), Alexa Fluor 
700-CD45 (30-F11), PE-IFN-γ (XMG1.2), and PE-Cy7-IL-4 (BVD4-24G2) were purchased 
from eBiosciences. 
Determination of BALF Cellularity and Cytokine Production 
BALF was isolated in 1 ml of PBS containing 2% heat-inactivated FBS as a protein 
carrier.  The total cell number was determined using a hemocytomer.  Cells (20,000) were 
cytospun onto slides, stained using a HEMA-3 staining kit (Fisher Scientific), and were counted 
by two independent observers.  Differential cell counts were based on cell morphology and 
staining.   
Cytokine concentrations in the BALF were measured using a multiplex suspension array 
system (X-Plex Mouse Assay and Bio-Plex 200 platform; BioRad Laboratories).  A total of 
seven cytokines were measured simultaneously in each sample, including IL-4, -5, -6,-10, -13, -
17, and IFN-γ, as per the manufacturer’s instructions.  The sensitivity varied for each cytokine 
(0.19 to 1.66 pg/ml). 
Lung Histology 
Lungs were perfused with PBS containing 20 U/ml heparin, inflated to total lung 
capacity, and fixed in HistoChoice Tissue Fixative (Amresco, Inc).  After serial dehydration, 
lungs were embedded in paraffin and sectioned at 4 µm.  Lung sections were then stained with 
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either hematoxylin and eosin (H&E) to characterize the cellular infiltrates or periodic acid-Schiff 
(PAS) to identify mucus-productive goblet cells in airways.  Micrographs of representative areas 
of lungs were taken under bright field with 100 x magnification (H&E) or 400 x magnification 
(PAS). 
Measurement of Pulmonary Function 
Respiratory mechanics were measured using an invasive method on a FlexiVent system 
(SCIREQ Scientific Respiratory Equipment Inc).  Mice were anesthetized, intubated, and 
ventilated using a computer controlled-ventilator.  Mice were then challenged with increasing 
doses (0, 12.5, and 25 mg/ml) of nebulized methacholine (MeCh; Sigma).  Lung pressure and 
volume changes after each challenge with MeCh were recorded and converted into digital 
signals, which the FlexiVent software fit into a single-compartment model to calculate lung 
resistance and compliance data (FlexiVent, version 5.2) 
Statistics 
Statistical calculations were performed using GraphPad Prism software (GraphPad 
Software, Inc.).  Student’s t-test was use to compare means between different groups with the 
exception of pulmonary function data.  Two-way ANOVA was used to analyze pulmonary 
function data, with a Bonferonni adjustment for pair-wise comparisons.  Data are expressed as 
means ± SEM, and p ≤ 0.05 was chosen as the significance level. 
Results 
Administration of IL-4Rα ASO Downregulated the Expression of IL-4Rα on Lung Cells 
After ASO treatment, flow cytometry was performed to examine the expression levels of 
IL-4Rα on lung cells including epithelial cells, T cells, and mDCs.  The IL-4Rα expression 
levels were quantified as the mean fluorescence intensity (MFI) of the antibody to IL-4Rα.  As 
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shown in Figure 3.2, surface IL-4Rα was significantly down regulated on both CD4+ T cells and 
mDCs in mice treated with IL-4Rα ASO, compared to control mice receiving saline (SAL 
group) or MM (MM group).  In fact, IL-4Rα expression in the ASO group was reduced by 15% 
on CD4+ T cells and 40% on mDCs.  Expression of IL-4Rα on CD8+ T cells and lung epithelial 
cells was not changed compared to the SAL group.  Down regulation of IL-4Rα was specific to 
the ASO group, since IL-4Rα expression on any cell type examined did not differ significantly 
between the MM and SAL groups. 
Administration of IL-4Rα ASO Altered T Lymphocyte Responses to Primary RSV 
Infection 
IL-4 is a Th2 cytokine important in Th2 cell maturation and effector functions.  
Therefore, instillation of IL-4Rα ASO was expected to influence the development of Th2 cells in 
RSV-infected animals.  To study this, mice were treated with ASO and infected with RSV (AR; 
Figure 3.1).  Three control groups were included: SHAM (treated with saline and media, as 
appropriate), RSV (treated with saline and infected with RSV), and MR (treated with MM and 
infected with RSV).  Flow cytometry was then performed to identify T helper cell populations  
 
 
 
 
 
 
 
 
 
Figure 3.2  Expression of IL-4Rα on lung cells.  Mouse pups were treated with ASO, MM, 
or saline (SAL) on protocol days -5, -3, and -1.  Twenty-four hours later, single lung cells 
were isolated and stained with antibodies to IL-4Rα and specific differentiating surface 
markers.  The levels of IL-Rα expression were determined by flow cytometry and plotted as 
the mean fluorescence intensity (MFI) of gated cells.  n=3. *p<0.05. 
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and cytotoxic T cell populations (CTLs; CD8+ T cells).  Like T helper cells, CTLs are also 
categorized into two subsets, based on the cytokines that they produce: Tc1 (IFN-γ producing) 
and Tc2 (IL-4 producing).  As shown in Figure 3.3, RSV-infected pups induced a mixture of Th1 
(IFN-γ+ CD4+), Th2 (IL-4+ CD4+), Tc1 (IFN-γ+ CD8+), and Tc2 (IL-4+ CD8+) cells in the 
infected lungs.  Instillation of IL-4Rα ASO altered the primary T cell responses to RSV 
infection, as evidenced by the significantly increased percentage of pulmonary Th1 cells and the 
decreased percentage of Th2 cells.  The percentage of Th1 cells in the AR mice was three fold 
higher than in the RSV mice, while the percentage of Th2 cells was reduced by half compared to 
the RSV mice.  No differences were observed in either type of CD8+ T cells between the AR and 
RSV groups.  Furthermore, no differences were observed in the MR and RSV groups.   
Administration of IL-4Rα ASO Increased Viral Load during Primary RSV Infection 
Pulmonary viral load may be associated with increased severity induced by RSV 
infection in some human cases (Fodha et al., 2007).  To address the possible effects of ASO 
treatment on RSV replication in the lung, pulmonary viral loads were measured at 4 dpi. 
Interestingly, viral loads in both the MM and ASO treated mice (MR and AR, respectively) were 
elevated compared to mice not receiving ASO/MM (RSV; Figure 3.4).  While RSV-infected 
lungs had mean viral loads of 104 TCID50/g lung tissue, both AR and MR mice exhibited 
significantly higher viral loads (104.8 and 104.6 TCID50/g lung tissue, respectively).   
Treatment with IL-4Rα ASO during Primary RSV Infection Prevented Airway 
Hyperreactivity upon Rechallenge 
Neonatally infected mice and infants develop severe respiratory distress, characterized by 
increased airway hyperresponsiveness, upon reinfection (Dakhama et al., 2005; Kim et al., 
1969).  To address the effects of IL-4Rα ASO treatment on pulmonary function following  
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Figure 3.3  T cell responses to neonatal RSV infection in the presence or absence of ASO 
treatment.  Four groups were incorporated in the study: one experimental group (AR) and 
three control groups (SHAM, RSV, and MR).  In the AR group, mouse pups were treated 
with IL-4Rα ASO on protocol days -5, -3, -1, and 1 and were then infected with RSV on 
protocol 0.  On protocol day 6, lung cells were isolated, stimulated in vitro, stained with 
differentiating markers, and analyzed by flow cytometry.  SHAM mice were treated with 
saline and media as appropriate; RSV mice received saline and RSV; and MR mice received 
MM and RSV.  n=3. ***: p<0.001, **: p<0.01, *: p<0.05, compared to SHAM mice; ##: 
p<0.01 compared to RSV group. 
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secondary RSV infection, neonatally infected mice were reinfected with RSV at six weeks of 
age.  Six days later, pulmonary function was tested.  The results are shown in Figure 3.5.A.  
Airway resistance to MeCh was similar between ASO-treated mice (ARR) and SHAM mice 
(Figure 3.5.A).  In contrast, non-treated (RR) and MM-treated mice (MRR) showed significant 
airway hyperreactivity in response to MeCh.  In fact, lung resistance at 50 mg/ml of MeCh in the 
RR and MRR mice was about 2.5-fold higher than in the SHAM or ARR mice.  Lung 
compliance followed the same trend (Figure 3.5.B).  Compliance in the ARR mice was similar to 
that in the SHAM mice, while both RR and MRR mice showed substantially lower compliance at 
50 mg/ml of MeCh (1.5-and 1.8-fold, respectively) compared to the SHAM or ARR group. 
IL-4Rα ASO Treatment Altered BALF Cellularity and Cytokine Levels upon RSV 
Reinfection 
BALF cellularity is an indication of inflammation occurring in airways and alveolar 
spaces, and therefore was determined at 6 dpi.  As shown in Figure 3.6.A, secondary infection  
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.4  Pulmonary viral load following primary RSV infection in neonatal mice 
treated with IL-4Rα ASO.  Viral titers were measured in lung homogenates at four days 
post-infection (dpi), using the TCID50 method.  n=4-6. ##: p<0.01, ###: p<0.001, compared to 
RSV group. 
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Figure 3.5  Pulmonary function after secondary RSV infection in mice receiving IL4Rα 
ASO during primary infection as neonates.  Mice infected with RSV as neonates were 
reinfected at six weeks of age.  Six days later, pulmonary function was tested in four groups.  
ARR mice received ASO treatment during primary infection and were reinfected with RSV 
as adults.  Control groups were MRR (treated with MM and RSV), RR (treated with saline 
and RSV), and SHAM (treated with saline and media as appropriate).  A) Lung resistance 
was determined and normalized to baseline resistance at 0 mg/ml of MeCh and was plotted as 
normalized resistance in response to increasing doses of MeCh.  B) Lung compliance was 
normalized to baseline compliance at 0 mg/ml of MeCh and was plotted as normalized 
compliance in response to increasing doses of MeCh.  n=5-6. *: p<0.05, **: p<0.01, ***: 
p<0.001, compared to SHAM mice; ##: p<0.01, ###: p<0.001, compared to RR group. 
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Figure 3.6  BALF cellularity and cytokine levels after secondary RSV infection.  
Neonatally infected mice were reinfected with RSV at six weeks of age.  BALF cellularity 
and cytokine production were determined at 6 dpi.  A) BALF cellularity.  Tot: total; Eos: 
eosinophils; Mac: monocytes/AMs; Neu: neutrophils; Lym: lymphocytes.  B) Cytokine levels 
in the BALF.  n=4-8; *: p<0.05, **: p<0.01, ***: p<0.001, compared to SHAM mice; #: 
p<0.05, ##: p<0.01, ###: p<0.001, compared to RR mice. 
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with RSV elicited a significant increase of BALF cellularity in all three infected groups of mice 
(RR, MRR, and ARR); however, IL-4Rα ASO-treated mice (ARR) had significantly lower total 
BALF cellularity compared to the RR group.  Furthermore, the composition of the BALF 
differed among these groups.  All three infected groups of mice recruited neutrophils, 
lymphocytes, and eosinophils into the airway.  ARR mice recruited significantly fewer 
eosinophils and monocytes/AMs compared to the RR mice.  No significant differences were 
observed between MRR and RR mice in either cell types or total cellularity. 
BALF cytokine levels were also measured at 6 dpi (Figure 3.6.B).  RSV reinfection 
resulted in secretion of a variety of cytokines, including IL-4,-5, -6, -10, -13, -17, and IFN-γ.  IL-
4Rα ASO treatment (ARR) during primary infection in neonatal mice led to a reduction of Th2 
cytokines including IL-4, IL-5, and IL-13.  The decreased Th2 cytokine production in the BALF 
was consistent with the reduced eosinophilia in the BALF of ARR mice.  No differences were 
observed between ARR mice and non-treated mice (RR) in other cytokines, including the 
prominent Th1 cytokine IFN-γ.  The BALF cytokine profile observed in mice receiving MM 
(MRR) was similar to that of the RR mice, with the exception of elevated IL-6 secretion. 
Administration of IL-4Rα ASO Reduced Lung Histopathology Induced by Secondary RSV 
Infection 
Secondary RSV infection in mice infected originally as neonates typically induces severe 
lung pathology, characterized by substantial inflammation and goblet cell hyperplasia.  This 
pulmonary pathology is regulated in part by Th2 cells and Th2 cytokines — in particular IL-13 
(Dakhama et al., 2005).  To determine if the improved pulmonary function in ASO-treated mice 
was associated with reduced pathology, lung histopathology was performed at 6 dpi.  
Interestingly, no observable differences were found in the magnitude of inflammation among the  
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Figure 3.7  Lung histology after secondary RSV infection.  Neonatally infected mice were 
reinfected with RSV at six weeks of age.  Lung sections were prepared and stained with H&E 
or PAS at 6 dpi.  The micrographs shown are representative of data from three mice.  A) H&E 
staining to identify inflammatory cells.  Bar=200 µm.  B) PAS staining (purple) to identify 
mucus in goblet cells.  Bar=50 µm.   
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three RSV-infected groups (RR, MRR, and ARR; Figure 3.7.A).  All three groups showed 
perivascular and peribronchiolar foci of inflammation with occasional diffuse alveolitis.  
Consistent with BALF cellularity, the inflammatory cells in the lungs also included monocytes, 
neutrophils, eosinophils, and lymphocytes.  No inflammation was observed in the lungs of 
SHAM mice.  In addition, secondary RSV infection also led to goblet cell hyperplasia and mucus 
hyperproduction in the bronchioles of RR and MRR mice (Figure 3.7.B).  Intriguingly, treatment 
with IL4Rα ASO significantly reduced goblet cell hyperplasia and mucus hyperproduction, as 
evidenced by the fact that only one or two foci of goblet cells were observed per lung section in 
the ARR group.  No differences in mucus staining were observed between the RR and MRR 
groups. 
Administration of IL-4Rα ASO Altered T Lymphocyte Responses to Secondary RSV 
Infection 
To address the possible mechanisms by which IL-4Rα ASO treatment alleviated 
pulmonary distress upon RSV reinfection, T cell responses (i.e., Th1/Th2 and Tc1/Tc2 
responses) were investigated using flow cytometry.  Th1, Th2, Tc1, and Tc2 cells migrated to 
lungs, as evidenced by significantly higher numbers of all four cell types in the lungs of RSV-
infected mice (RR, MRR, and ARR) than in the SHAM mice.  Treatment with IL-4Rα ASO led 
to a significant reduction in Th2 cell recruitment (by about 50% in the RR mice) upon secondary 
RSV infection (Figure 3.8.A).  Although not significant, ARR mice showed an increased Tc1 
response compared to the RR mice.  Treatment with MM (MRR) failed to show any effects on 
secondary T cell responses (compare MRR to RR). 
Discussion 
The present study demonstrated that seven day old mice infected with RSV developed 
severe pulmonary diseases when reinfected with RSV at six weeks of age.  Pulmonary disease  
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Figure 3.8  Pulmonary T cell populations following secondary infection with RSV.  
Neonatally infected mice were reinfected with RSV at six weeks of age.  Single lung 
suspensions were prepared, stimulated, stained with various antibodies, and analyzed by flow 
cytometry to examine T cell subsets recruited to the lung at 6 dpi.  A) T cell subpopulations 
in the lungs after secondary infection.  B) Dot plots representing IL4+ CD4+ T cell 
population (upper right quadrant) following secondary infection.  n=3; *: p<0.05, **: p<0.01; 
***: p<0.001, compared to the SHAM mice; #: p<0.05, compared to the RR group.  
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was characterized by airway hyperreactivity, inflammation, goblet cell hyperplasia, and mucus 
hyperprodcution.  Immunologically, the illness correlated with Th2 cell infiltration and effector 
functions including eosinophilia and the release of Th2 cytokines (IL-4, IL-5, and IL-13).  When 
ASO to IL-4Rα were administered during primary RSV infection, the majority of the RSV-
mediated immune-physiological responses were suppressed upon reinfection.  These included 
diminished Th2 cellular infiltration, Th2 cytokine secretion, eosinophilia, goblet cell hyperplasia, 
and abolished airway hyperreactivity in response to MeCh. 
The most intriguing result was not that treatment with IL-4Rα ASO altered the Th1/Th2 
balance during primary infection in the neonates, but that the treatment completely inhibited 
pulmonary dysfunction upon reinfection.  This ablation of pulmonary dysfunction may be 
attributed to the reduced Th2 primary responses, including a reduction of IL-13 in the BALF of 
ASO-treated mice, since depletion of IL-13 during RSV reinfection has been shown to abolish 
mucus hyperproduction and airway hyperreactivity (Dakhama et al., 2005).  Although not tested 
in the present study, the reduction of primary Th2 responses most likely led to a decrease in 
memory Th2 responses to reinfection and may be explained as follows: ASO treatment down-
regulated IL-4Rα expression on mDCs, the professional antigen presenting cells in the lung.  
After taking up the virus, mDCs migrated to draining lymph nodes and presented the virus to, 
activated, and provided differentiating signals to naïve T cells (de Jong et al., 2005; Kalinski et 
al., 1999; Kapsenberg, 2003).  The major differentiating signal for Th2 cell commitment is IL-4, 
and IL-4 stimulates mDCs via IL4Rα to produce more IL-4 (Maroof et al., 2006).  Therefore, the 
down regulation of IL-4Rα expression on mDCs may have inhibited primary Th2 cell 
differentiation, which could have led to the decreased number of Th2 cells observed in the 
present study (Figure 3.3).  After activation and differentiation, a subset of Th2 cells develops 
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into memory cells, which circulate in the body to respond rapidly if a secondary infection occurs.  
Upon reinfection, fewer Th2 recall responses were observed in ASO-treated mice (Figure 3.8), 
most likely due to the reduced Th2 cellular memory response upon primary infection. 
Despite the moderate increase in Th1 responses in ASO-treated mice during the primary 
infection, we found no difference in Th1 cells upon reinfection (compare ARR and RR groups).  
This may be due to the recruitment of nonspecific Th1 cells to the infected lungs upon primary 
infection or to the failure to create memory Th1 cells; laboratory studies are currently being 
performed to test this hypothesis.  
Notably, the present study provides a possible vaccine strategy for RSV via 
immunomodulation at the time of vaccination.  Developing vaccines for infants is difficult, due 
to their relatively immature immune systems, which favor a Th2 response instead of a protective 
Th1 response.  In the infamous RSV vaccine trial of the late 1960s, 80% of the children 
vaccinated with formalin-inactivated RSV developed severe bronchiolitis and/or pneumonia 
upon naturally acquired reinfection.  Two of the thirty-one vaccinated infants died.  Autopsies on 
the lungs from these infants showed tremendous pulmonary inflammation and eosinophilia, 
indicating an exacerbated Th2 response.  Our data demonstrate that treatment with IL-4Rα ASO 
increases the ratio of Th1 to Th2 cells during primary infection and, more importantly, that this 
mild push away from a Th2 response and toward a Th1 response during primary RSV infection 
leads to a balanced secondary Th1/Th2 response and ablation of pulmonary dysfunction upon 
reinfection.  The data indicate that the rebalancing of Th1 and Th2 responses appears to have 
been achieved by a decrease in the number of Th2 cells in ASO-treated mice rather than an 
increase in the number of Th1 cells.   
Excluding the possible recruitment of non-specific Th1 cells, this phenomenon actually 
has its advantages.  Too many Th1 cells and an exaggerated Th1 response could lead to 
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bystander tissue damage and enhanced disease severity, as eloquently demonstrated by 
Openshaw and colleagues with a recombinant RSV expressing IFN-γ (rRSV/IFN-γ) (Harker et 
al., 2007).  In these studies, overexpression of the Th1 cytokine IFN-γ led to detrimental effects 
on the disease severity induced by RSV reinfection, as evidenced by enhanced weight loss in 
mice originally infected with rRSV/IFN-γ.  In fact, mice infected with rRSV/IFN-γ developed 
more severe pulmonary inflammation upon rechallenge, characterized by massive pulmonary 
inflammation of Th1-related Tc1 cells, compared to mice infected with wild-type RSV. 
In summary, using antisense oligonucleotides against IL-4Rα during primary RSV 
infection in neonatal mice abolished the pulmonary dysfunction normally observed following 
rechallenge in adults.  This ablation of pulmonary dysfunction correlated with decreased Th2 
responses including reduced eosinophilia, Th2 cytokine secretion, and goblet cell hyperplasia.  In 
short, treatment with the IL-4Rα ASO during primary RSV infection in neonatal mice succeeded 
where the 1960s vaccine trial failed.  In combination, our data suggest that interventional 
therapy, during the initial RSV infection, with IL-4Rα ASO may be of significant benefit. 
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CHAPTER FOUR: 
INCHOATE CD8+ T CELL RESPONSES IN NEONATAL MICE 
PERMIT INFLUENZA INDUCED PERSISTENT PULMONARY 
DYSFUNCTION 
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Introduction 
Each year influenza viruses cause significant morbidity and mortality (2000).  Influenza 
virus A, in particular, has been shown to elicit respiratory illnesses such as pneumonia and 
bronchiolitis and to exacerbate underlying respiratory diseases such as chronic obstructive 
pulmonary disease (COPD) and asthma (Upshur et al., 2006).  In fact, last winter (Oct 2006 to 
May 2007), 23,753 specimens tested positive for influenza viruses in collaborating laboratories 
of the World Health Organization and the National Respiratory and Enteric Virus Surveillance 
System in the United States (http://www.cdc.gov/flu/weekly/weeklyarchives2006-2007/06-
07summary.htm).  Of the influenza positive specimens, 79% were influenza A viruses and 62% 
of these were of the H1 subtype (http://www.cdc.gov/flu/weekly/weeklyarchives2006-2007/06-
07summary.htm).  Interestingly, the highest incidence of illness occurs in pre-school and school 
age children with 20 to 30% of children in this age group being diagnosed with influenza 
infections each year (Chin et al., 1960; Collins and Lehmann, 1951; Glezen, 1996; Glezen et al., 
1997).  Infected infants younger than six months of age have higher hospitalization and mortality 
rates than do older children (Ajayi-Obe et al., 2007; Bhat et al., 2005).  Complications of 
influenza infections in infants typically include lower respiratory tract involvement and although 
these infections occur less frequently than respiratory syncytial virus (RSV) infections in infants, 
they are also a significant cause of wheeze (Neuzil et al., 2002).  Epidemiological data 
demonstrate that infection of infants with influenza can lead to chronic pulmonary distress and 
furthermore that the effects of influenza in this population are underestimated and may be 
responsible for previously unexplained chronic pulmonary dysfunction (Laraya-Cuasay et al., 
1977). 
To understand how influenza induces pulmonary illness, various animal models have 
been used, including ferrets, rats, chickens, and mice (Eichelberger, 2007).  While neutralizing
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antibodies to influenza are important for protection from viral infection, CD8+ T cells have been 
shown to play a pivotal role in viral clearance and recovery from the illness in adult mice.  CD8+ 
T cell deficient mice exhibit delayed viral clearance and significantly higher mortality when 
challenged with a sub-lethal dose of influenza (Bender et al., 1992).  In addition, in B cell 
deficient mice, adoptive transfer of CD8+ T cells promotes more rapid clearance of the virus and 
recovery from illness (Epstein et al., 1998; Graham and Braciale, 1997). 
Despite the global burden of influenza infection in infants and children, very few studies 
have examined the pathogenesis of infection in an infant model.  The infant and neonatal 
immune systems are immature and this immaturity contributes to the pathogenesis of various 
lower respiratory tract infections including influenza, RSV, and others.  Lower respiratory tract 
viral infections in infants are often associated with acute and persistent pulmonary dysfunction, 
which is characterized by increased airway resistance and hyperresponsiveness (Pullan and Hey, 
1982; Sigurs et al., 2000; Sigurs et al., 2005).  Previously, we and other groups have described a 
neonatal mouse model (i.e., 7d of age at initial infection) of RSV infection (Culley et al., 2002; 
Dakhama et al., 2005; You et al., 2006).  In this model, the age of primary infection determined 
the immunological nature (Th1 or Th2) of the secondary infection.  Th2 immune responses 
dominated upon secondary infection, if the primary infection occurred at 1 week or less of age; 
while Th1 responses dominated if the mice were primarily infected as adults (8 wk old) (Culley 
et al., 2002).  Interestingly, a single infection with RSV in neonatal mice induced long-term 
pulmonary dysfunction (You et al., 2006); which was exacerbated upon secondary infection with 
RSV (Dakhama et al., 2005).  The RSV neonatal model demonstrated that the age at which the 
initial infection occurred is critical in determining the subsequent host immune response to the 
pathogen; and furthermore, it suggested that if the infection occurs too early, the immature 
immune response contributes to pathogenesis instead of protection. .
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A recent study in human infants suggests that a failure to develop a cytotoxic T 
lymphocyte response is responsible for the high rate of infant morbidity and mortality caused by 
respiratory viruses (Welliver et al., 2007).  The article demonstrated that in both fatal infant 
influenza and RSV infection, CD4+ and CD8+ T cells were present in the lung at very low 
frequency.  In addition, granzyme-producing cells (either cytotoxic CD8+ T cells or NK cells) 
were not observed in the lungs of infants with fatal influenza virus infection and correlated with 
massive viral replication and apoptosis of inflammatory cells. 
To understand the relationships among the type of respiratory virus, the pulmonary 
immune response and the long-term pulmonary pathophysiology after infection in infancy, we 
established a neonatal (seven day of age) mouse model of influenza A virus infection.  In this 
model, neonatal infection induced long-term pulmonary inflammation and airway injury and 
dysfunction accompanied with a weak CD8+ T cell response (lower number and lower IFN-γ  
production in CD8+ T cells).  To examine if the weak CD8+ T cell response played a role in the 
pathogenesis of influenza infection in neonates, we adoptively transferred adult CD8+ T cells 
into neonatal mice prior to infection with influenza.  Our data demonstrate that the insufficient 
production of IFN-γ by neonatal CD8+ T cell may be responsible for the long-term pulmonary 
inflammation and lung injury in influenza infected neonatal mice.  
Materials and Methods 
Mice 
BALB/c mice were purchased as breeders from Harlan Sprague Dawley, Inc.  IFN-γ 
knockout mice (C.129S7 (B6)-Ifngtm1Ts/J) were purchased from the Jackson Laboratory.  Mice 
were maintained under specific pathogen-free conditions within the vivarium at Louisiana State 
University Health Sciences Center (New Orleans, LA).  Sentinel mice within each colony were 
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monitored and were negative for specific known mouse pathogens.  Breeders were time-mated 
and seven-day-old pups (neonates) were used for experiments.  All animal protocols were 
prepared in accordance with the Guide for the Care and Use of Laboratory Animals (National 
Research Council, 1996) and approved by the Institutional Animal Care and Use Committee at 
Louisiana State University Health Sciences Center. 
Viral Infection and Viral Titer Determination 
Human Influenza A/PR/8/34 (H1N1) was purchased as a sucrose-gradient purified virus 
from Advanced Biotechnologies, Inc.  The virus preparation was determined to be free of 
bacteria, yeast, and fungi.  Viral titer was measured in whole lung homogenates at different time 
points (Figure 4.1) using the TCID50 method of Spearman-Kärber (Karber, 1931; Spearman, 
1908).  Mardin-Darby canine kidney cells were seeded on a 96-well plate and then inoculated 
with a series of 10 fold dilutions of lung homogenates.  Cells were then incubated at 37 °C and 
5% CO2 for four days; wells showing cytopathic effects were counted and TCID50 were 
calculated.  
Experimental Design 
Seven day old pups were infected intranasally with 10 TCID50/g body weight of influenza 
(FLU) in 10 µl of DPBS or sham infected with 10 µl DPBS (SHAM).  Mouse pups were then 
allowed to mature and various assays performed at the indicated time points as outlined in Figure 
4.1.A.  For adoptive transfer studies, CD8+ T cells from naïve wild-type adults (FLU/CD8A), 
wild-type neonates (FLU/CD8N), or IFN-γ knockout mice (FLU/CD8AKO) were administered 
intraperitoneally to six-day-old pups; and at seven day of age, these pups were then infected with 
influenza (Figure 4.1.B).  Four groups of mice were included as controls: vehicle treated pups 
(SHAM), influenza infected pups (FLU), vehicle treated adult mice (ASHAM), and influenza 
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infected adult mice (AFLU).  A range of assays were performed at indicated time points as 
shown in Figure 4.1.B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Function Test 
Pulmonary function, specifically the respiratory mechanics, were measured using an 
invasive method as previously described (You et al., 2006).  Briefly, anesthetized mice were 
intubated and mechanically ventilated by a computer controlled piston ventilator (FlexiVent, 
SCIREQ).  Mice were then challenged by an aerosolized bronchoconstrictor methacholine 
(Sigma) at increasing doses (MeCh: 0, 25, and 50 mg/ml).  At each dose, lung resistance and 
compliance were calculated using the single compartment model.  
 
Figure 4.1  The study protocol for the experiments.  A) seven day old mouse pups were 
infected intranasally with 10 TCID50 H1N1/g whole body weight (FLU); while a control 
group of mice were mock-infected with vehicle (SHAM).  BALF was isolated at 0.2, 2, 4, 10, 
and 109 dpi.  Lungs were isolated for viral titer assays at 2, 5, and 10 dpi; for histopathology 
at 10 and 109 dpi; and for evaluation of T cell subpopulations (T pop) at 7 dpi.  Pulmonary 
function (PFT) was tested at 109 dpi.  B) For the adoptive transfer study, 6 d old pups were 
administered CD8 T cells purified from the spleens of naïve neonatal (7 d old, CD8N), adult 
(4 wk old, CD8A) , or adult IFN-γ deficient (4 wk old, CD8AKO) mice.  Pups were infected 
with influenza (FLU) at 7 d of age and allowed to mature until 37 d of age (30 dpi).  Four 
control groups were included: neonatal or adult non-infected mice (SHAM and ASHAM, 
respectively) and neonatal or adult influenza infected (FLU and AFLU, respectively).  Viral 
titers were measured at 4 and 30 dpi.  Pulmonary function test, BALF cellularity, and lung 
histopathology were measured at 30 dpi.   
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Lung Histopathology 
At different time points, lungs were perfused, inflated by gentle infusion of HistoChoice 
Tissue Fixative (Amresco, Inc) to tidal volume (6 ml/kg), and isolated (Figure 1).  The fixed 
lungs were then dehydrated, embedded in paraffin, and sectioned at 4 µm.  Each lung section 
was stained with either hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS).  Specific 
histopathological diagnoses were performed by unbiased pathologists (D. T. and D. S.). 
Initial observations of the influenza infected lungs suggested emphysematous-type 
lesions.  Morphometric analyses of the lung sections were used to quantify these changes in lung 
architecture including airspace enlargement (i.e., mean linear intercept; Lm) and destruction of 
the alveolar walls (i.e., destructive index; DI).  Lm was quantified using NIH-Image 
(http://rsb.info.nih.gov/nih-image).  The number of alveolar wall intersections was counted on 12 
non-overlapping lung fields and was expressed as µm using a protocol adapted from Thurlbeck 
(Thurlbeck, 1967).  To measure DI, a grid with 42 equidistant points (100 µm between each 
point) was placed at the center of and superimposed on the lung field.  Structures lying under 
these points were classified as normal (N) or destroyed (D) alveolar and/or duct spaces.  Points 
falling over other structures, such as duct walls, alveolar walls, etc. were excluded from the 
calculations.  The DI was calculated from the formula: DI = D / (D + N) x 100 (Saetta et al., 
1985). 
Bronchoalveolar Lavage Fluid Cellularity and Cytokine Measurement 
Bronchoalveolar lavage fluid (BALF) was isolated in 1 ml of PBS containing 2% heat 
inactivated FBS at the indicated time points (Figure 1).  The cells were then centrifuged onto 
slides and stained using a Hema-3 staining kit (Fisher).  Two unbiased readers counted a total of 
300 cells per slide and recorded the differential cell counts based on the morphology and staining 
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of the cells.  Cytokine levels were measured from 50 µl of cell-free BALF using a high-
throughput multiplex cytokine assay system (X-Plex Mouse Assay; BioRad) according to the 
manufacturer’s instructions.  Each sample was analyzed in triplicate on the Bio-Plex 200 system 
(BioRad).  A broad sensitivity range of standards ranging from 1.21 to 37,312 pg/ml (depending 
on the analyte) was used to quantitate a dynamic range of cytokine concentrations.  The 
concentrations of analytes in these assays were quantified using a standard curve and a 5-
parameter logistic regression was performed to derive an equation that was then used to predict 
the concentration of the unknown samples. The following cytokines were assayed: IL-2, IL-4, 
IL-5, IL-6, IL-12(p40), IL-13, IL-17, IFN-γ, and TNF-α.  The data presented here excluded any 
number below the range of sensitivity for the particular analyte. 
Assessment of Pulmonary T Cell Populations 
A single cell suspension of lung cells was prepared using a standardized protocol 
(Ormerod, 2000).  Briefly, lungs were perfused, excised, cut into small pieces and incubated at 
37°C for 1 hour in RPMI-1640 media supplemented by 2% heat inactivated FBS, 1 mg/ml 
Collagenase I (Invitrogen), and 150 µg/ml DNase I (Sigma).  After incubation, single cells were 
obtained by mashing the lung pieces through a 40 µm cell strainer (BD Biosciences).  Red blood 
cells were lysed using 1X RBC lysis buffer (eBioscience) and the remaining cells were 
stimulated for 5 hours with 5 ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma) and 500 
ng/ml ionomycin (Sigma) in the presence of a protein transport inhibitor (1µl/1 x 106 cells; 
GolgiPlug, BD Biosciences).  After stimulation, cells were harvested, fixed, and permeabilized 
(fixation and permeabilization buffer; eBioscience), and stained with the following antibodies 
purchased from eBioscience: Pacific Blue-CD3 (17A2), PerCP-CD4 (RM4-5), Alexa Fluor 488-
CD8a (53-6.7), PE-IFN-γ (XMG1.2), and PE-Cy7-IL-4 (11B11).  In order to evaluate influenza 
 74 
specific CD8+ T cell response, lung cells were stained with APC-labeled H-2Kd tetramer 
complexed with the immunodominant epitope TYQQRTRALV (H-2Kd/TYQQRTRALV, 
Immunomics) from influenza A nucleoprotein (NP) without PMA/ionomycin stimulation.  After 
staining, cells were fixed in a paraformaldehyde-based fixative (BD Stabilizing Fixative) and 
assessed with an LSRII (BD Biosciences) flow cytometer.  The staining profiles of different cells 
were analyzed and plotted using FlowJo software (Version 7.2.2 for Windows, Tree Star, Inc) 
after gating on the lymphocyte population as determined by forward and side scatter properties. 
Adoptive Transfer of CD8+ T Cells 
The protocol is modified from the method developed by Wells et al (Wells et al., 1981).  In brief, 
single cell suspensions were prepared from the spleens of adult (4 wks of age), adult IFN-γ 
knockout mice (4 wks of age) or neonatal (7 day of age) mice using a standardized protocol as 
described in the method section — “assessment of pulmonary T cell populations”.  CD8+T cells 
were isolated using a negative selection strategy according to the manufacturer’s instructions 
(Mouse CD8+ T cell enrichment kit; Stem Cell).  Neonatal, adult, or IFN-γ knockout adult CD8+ 
T cells (4 x 106) were then resuspended in 25 µl of sterile PBS, and injected intraperitoneally 
into six-day-old pups (CD8N, CD8A, CD8AKO, respectively). 
Statistical Analysis 
All data were plotted as mean ± SEM and analyzed using GraphPad Prism (GraphPad 
Software Inc., Version 5.0.0).  Two-way ANOVA and Bonferroni post-tests were used to test for 
differences between the groups for the pulmonary function, BALF cellularity, cytokine assays, 
and T cell populations.  Student’s T test was used to analyze the differences in lung 
histopathology parameters (Lm and DI).  Differences before groups were considered statistically 
significant if p < 0.05. 
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Results 
Neonatal Influenza Infection Resulted in Acute Pulmonary Inflammation 
BALB/c pups were infected at 7 d of age with 10 TCID50 of influenza A virus/gram body 
weight (FLU); controls received sterile DPBS (SHAM).  Mice infected with this sublethal dose 
>90% survival) of influenza developed mild-to-moderate illness, which was characterized by 
ruffled fur and significant reductions in weight gain compared to SHAM.  By 18 dpi, mice 
infected with influenza weighed 12% less than SHAM animals (p<0.05).  Infectious influenza 
virus was detected in whole lung homogenates in neonatal mice as early as 2 dpi (104.49±0.03 
TCID50/g lung tissue) and peaked at 5 dpi (106.93±0.25 TCID50/g lung tissue).  No infectious 
viruses were detected in neonatal or adult mice after 7 dpi. 
To measure pulmonary inflammation, bronchoalveolar lavage fluid (BALF) cellularity, 
BALF cytokine levels, and lung histopathology were monitored throughout the course of the 
infection (Figures 4.2 & 4.3).  All results from SHAM mice at different time points (5 hours, 1, 
2, 4, and 10 days post-infection) were similar and showed no difference (data not shown), 
therefore only data from 10dpi were presented as a representative.  Mice infected with influenza 
recruited significantly more inflammatory cells to the lung as observed in both the lung and the 
BALF.  Monocytes/AMs were shown to be recruited to the bronchoalveolar space as early as 5 
hours post-infection (hpi, Figure 4.2.A), and significantly more cells compared to SHAM were 
observed at 4 and 10 dpi with the peak at 10 dpi (44.09 ± 6.83 vs. 13.19 ± 1.92 x 104).  
Neutrophils in the BALF showed the same trend.  They peaked at 2 dpi (3.20 ± 1.11 vs. 0.12 ± 
0.02 x 104); and remained elevated at 10 dpi compared to SHAM (2.58 ± 0.75 vs. 0.08 ± 0.03 x 
104).  A significant increase in lymphocytes was observed at 10 dpi (8.47 ± 3.79 vs. 0.01 ± 0.01 
x 104).  Total BALF cell numbers were five-fold higher in the FLU group compared to the 
SHAM group at 10 dpi (61.30 ± 10.70 vs. 13.30 ± 1.92 x 104, p<0.05).
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Cytokines in the BALF peaked at various times during the infection (Figure 4.2.B).  
Although a total of ten cytokines (IL-2, -4, -5, -6, -12(p40), -12(p70),-13, -17, IFN-γ, and TNF-
α) were measured, only six (IL-5, -6, -12(p40), -13, IFN-γ, and TNF-α) were detectable at the 
time points tested.  Of those cytokines detected (with the exception of IFN-γ), all were elevated 
at 5 hpi.  TNF-α was one of the earliest cytokines detected and was present in the highest 
concentration at 5 hpi (72.0 ± 2.55 pg/ml).  It remained significantly elevated at 2 dpi (65.0 ± 
28.3 pg/ml) and was undetectable by 10 dpi.  IL-12(p40) gradually increased from 5 hpi to 10 
dpi; where it became significantly elevated over SHAM (61.4 ± 7.51 pg/ml).  IFN-γ was only 
detectable at 2 (20.1 ± 10.9 pg/ml) and 4 dpi (21.5 ± 0.00 pg/ml).  The other three cytokines (IL-
5, -6, and -13) were detected at all time points but not significantly different than in SHAM 
treated mice.   
Histopathologic examination of lungs from neonatally infected mice revealed marked 
pulmonary inflammation that was observed in the perivascular, peribronchial, and alveolar 
spaces of the lung at 10 dpi (Figure 4.3.A, right panel).  The inflammatory infiltrates consisted of 
lymphocytes and occasional plasma cells.  In addition, extensive mucus production was observed 
in the goblet cells of the infected lungs, along with proliferation of peribronchial glands within 
the hilum (Figure 4.3.B, right panel).  Diffuse emphysematous changes with a slight thickening 
of the alveolar walls and vascular congestion were also observed.  In contrast, SHAM lungs 
showed normal thickening of the alveolar wall with no inflammation (Figure 4.3.A, left panel) 
and no mucus staining (Figure 4.3.B, left panel). 
Neonatal Influenza Infection Led to Long-term Pulmonary Dysfunction and Injury 
In order to investigate the long-term effects of neonatal influenza infection, a group of 7 d 
old pups were infected with the virus and allowed to mature to 116 d of age (109 dpi, Figure  
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Figure 4.2  BALF cellularity and cytokine levels in neonatal mice after infection.  A) 
BALF was isolated and the cellularity determined at 5 hpi and at 2, 4, and 10 dpi.  Absolute 
cell numbers were plotted versus time post-infection.  n=4-5/group.  B) Cytokine levels in the 
BALF supernatant was determined for the following cytokines: IL-2, -4, -5, -6, -12(p40) -
12(p70),-13, -17, IFN-γ, and TNF-α.  Only detected cytokines are displayed on the graph.  
n=3-5/group.  Data are expressed as mean ± SEM, *: p<0.05, **: p<0.01, ***: p<0.001, 
compared to SHAM. 
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Figure 4.3  Lung histopathology following neonatal influenza infection.  Lungs were 
isolated, fixed and stained with H&E and PAS at 10 dpi.  A) H&E staining showed marked 
inflammation in the perivascular, peribronchial, and alveolar spaces of the lung (right panel).  
Diffuse emphysematous changes were also observed in the infected lungs along with slight 
thickening of the alveolar walls.  SHAM mice showed no inflammation or emphysematous 
changes (left panel).  Scale bar=100 µm.  B) PAS staining demonstrated widespread mucus 
production and proliferation of peribronchial glands within the hilum in the influenza infected 
mice (right panel).  SHAM mice showed no mucus staining.  Scale bar=50 µm.  Each picture 
is a representative of three different animals.   
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4.1.A).  As with the acute studies, BALF cellularity, BALF cytokine levels, and lung 
histopathology were recorded at 109 dpi.   
Significantly more total cells were present in the BALF of previously infected mice 
compared to SHAM animals at 109 dpi (6.05 ± 1.89 vs. 2.59 ± 0.70 x 105, p<0.05).  As shown in 
Figure 4.4, there were significantly more monocytes/AMs (51.02 ± 8.79 x 104) present in the 
BALF of infected animals compared to SHAM mice (25.08 ± 5.17 x 104).  Neutrophils (14.42 ± 
6.47 x 104) and lymphocytes (6.20 ± 3.24 x 104) were higher than SHAM (1.08 ± 0.53 and 0.25 
± 0.07 x 104, respectively), although not significantly different (p=0.074).  Eosinophils were not 
observed in the BALF of either FLU or SHAM mice.  None of the cytokines assayed in the 
BALF at 109 dpi were significantly different than that of controls (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4  BALF cellularity in adult mice infected with influenza as neonates.  BALF 
was isolated at 109 dpi and leukocyte populations determined.  Data were expressed as mean 
± SEM, n=4-5/group.  *: p<0.05. 
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The persistent change in BALF cellularity at 109 dpi suggested that there might also be 
unresolved pulmonary inflammation in the lungs of the adult mice initially infected with 
influenza as neonates.  Indeed, lung histopathologic examination (Figure 4.5.A, right panel) 
confirmed mild-to-moderate peribronchial chronic inflammation consisting mostly of 
lymphocytes.  Furthermore, moderate mucus production was still present in the goblet cells of 
infected lungs (Figure 4.5.B, right panel).  Diffuse emphysematous changes with focal areas of 
minimal thickening within the alveolar walls were also observed in the infected lungs.   
Emphysematous lesions were quantified by evaluating both the airspace enlargement in 
terms of Lm and the destruction of the alveolar walls by measurement of DI.  Influenza infected 
lungs exhibited a marked increase of alveolar enlargement (Lm 79.0 ± 2.89 μm) compared to 
SHAM (60.0 ± 5.15 μm) and a significant increase destroyed alveolar walls (DI: 57.1 ± 2.91 μm) 
versus SHAM (14.5 ± 0.58 μm). 
The change in the lung structure associated with the persistence of inflammatory cells in 
the lung and the BALF suggested alterations in pulmonary function.  To determine if neonatal 
infection with influenza produced long-term effects on lung function, lung mechanics were 
measured in mechanically ventilated animals at 109 dpi.  Mice infected with influenza as 
neonates showed significantly impaired lung function compared to the SHAM mice as evidenced 
by increased airway hyperreactivity with decreased dynamic compliance in response to MeCh 
(Figure 4.6.A & B).  Baseline resistance was similar in these two groups at this time point (0.49 
± 0.03 vs. 0.47 ± 0.08 cm H2O·s/ml).  Although there was no significant shift to the left in the 
MeCh dose response curve; influenza infection increased pulmonary resistance in response to 50 
mg/ml of MeCh (4.12 ± 0.93 vs. 1.25 ± 0.21 cm H2O·s/ml, Figure 4.6.A) and therefore, airway 
hyperreactivity. 
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Figure 4.5  Adult lung histopathology of mice infected with influenza as neonates.  Lungs 
were isolated, fixed and stained by H&E and PAS at 109 dpi.  A) Mild-to-moderate 
peribronchial chronic inflammation consisting mostly of lymphocytes and diffuse 
emphysematous changes were observed in the lungs of mice infected with influenza as 
neonates (right panel).  No inflammation or emphysematous changes was observed in SHAM 
mice (left panel).  Scale bar=100 µm.  B) Moderate mucus production persisted in airway 
epithelial cells of influenza infected mice (right panel); while no mucus staining was observed 
in the lungs of SHAM infected mice.  Scale bar=50 µm.  Each picture is a representative of 
three animals. 
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Figure 4.6  Persistent airway dysfunction in adult mice infected with influenza as 
neonates.  Pulmonary function was assayed at 109 dpi.  A) Influenza infected mice showed a 
significant increase in lung resistance compared to sham-inoculated mice when challenged by 
50 mg/ml methacholine (MeCh).  There was no difference in baseline resistance between the 
FLU and SHAM groups.  Data were normalized to baseline (0 mg/ml MeCh) and are 
expressed as mean ± SEM, n=5/group.  ***: p<0.001.  B) These same mice exhibited a 
marked decrease in lung compliance if they were infected.  For simplicity in interpretation, 
data are presented as normalized to baseline (0 mg/ml MeCh) and expressed as mean ± SEM, 
n=5/group.  **: p<0.01. 
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Reduced IFN-γ+ T Cells Are Observed in the Neonates in Response to Influenza Infection 
To dissect the possible mechanism(s) responsible for the observed long-term pulmonary 
dysfunction, pulmonary T cell responses were measured using intracellular cytokine staining in 
influenza infected neonates (FLU) and adults (AFLU; 4wk old) at 7 dpi.  Approximately, two-
fold more CD8+ T cells (9.7 ± 1.1 vs. 5.2 ± 1.3 x 105) and slightly more CD4+ T cells (1.67 ± 
0.18 vs. 1.41 ± 0.48 x 106) were present in the adult lungs compared to the neonatal lungs 
(Figure 4.7.B, left panel).  In addition, neonates infected with influenza appeared to mount a 
weak IFN-γ response to the virus, compared to that of adults (Figure 4.7.B, middle panel).  Adult 
mice infected with influenza (AFLU) were able to recruit almost six-fold more CD8+IFN-γ+ T 
cells (12.3 ± 1.92 vs. 2.76 ± 1.92 % of CD8+ T cells) and two-fold more CD4+IFN-γ+ T cells 
(4.04 ± 0.67 vs. 1.92 ± 0.34 % of CD4+ T cells) to the lung as compared to the neonates.  CD4+ 
IFN-γ+ T cells in neonates were statistically different from SHAM levels (0.61 ± 0.07 % of 
CD4+ T cells).  No difference was observed in the number of CD4+IL-4+ T cells recruited to the 
lungs of mice infected with influenza as neonates or adults (data not shown).  To examine the 
specificity of the CD8+ T cells recruited to the lung, we stained lung lymphocytes with H-2Kd 
tetramers containing the immunodominant epitope from the influenza nucleoprotein (Figure 
4.7.B right panel).  Influenza infection of adult mice resulted in the recruitment of about two-fold 
more CD8+ T cells that bound the influenza tetramer compared to infection of neonatal mice 
(2.29 ± 0.16% vs 1.24 ± 0.04%). 
Reversal of Long-term Pulmonary Dysfunction after Adoptive Transfer of Adult CD8+T 
Cells but not Neonatal CD8+ T Cells 
To determine whether the persistent pulmonary inflammation, altered lung structure, and 
long-term lung dysfunction were due to the functional immaturity of host lymphocytes or other 
factors (e.g., IFN-γ), CD8+ T cells were purified from the spleen of naïve neonatal, adult, or  
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Figure 4.7  Lymphocyte populations in the lungs of mice infected with influenza as 
neonates and adults.  T cell subpopulations were analyzed in lung homogenates at 7 dpi in 
mice infected at either 7 d (FLU) or 4 w (AFLU) of age using intracellular cytokine staining 
and flow cytometry.  A) A representative flow cytometry dot plot of IFN-γ+ CD4+ and CD8+ 
T cells in infected adult or neonatal mice.  B) Both CD4+ and CD8+ T cells appeared to be 
elevated in influenza infected adults (AFLU) compared to mice infected as neonates (FLU, 
left panel).  IFN-γ+ CD4+ and CD8+ T cells were significantly greater in influenza infected 
adults as compared to infected neonates (middle panel).  Finally, CD8+ T cells specific for an 
immunodominant epitope of influenza in AFLU mice were also significantly greater than in 
FLU mice (right panel). 
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adult IFN-γ deficient mice and adoptively transferred to 6 d old pups (Figure 4.1.B).  One day 
later, these mice were then infected with 10 TCID50/g body weight of influenza (FLU/CD8N, 
FLU/CD8A, or FLU/CD8AKO, respectively).  In addition, neonatal and adult mice were simply 
infected with influenza (FLU and AFLU, respectively).  Pulmonary function testing, BALF 
cellularity and lung histopathology were performed at 30 dpi.   
Both FLU/CD8N and FLU/CD8A groups showed an improvement in pulmonary 
function, as evidenced by lower airway hyperreactivity compared to control FLU mice (2.89 ± 
0.94 and 1.45 ± 0.46 vs. 5.17 ± 1.35 H2O·s/ml at 50 mg/ml MeCh, Figure 4.8.A).  Since non-
infected control mice, either adult or neonate at time of sham infection, exhibited almost 
identical responses (data not shown), therefore only the non-infected control mice that were 
sham infected as neonates (SHAM) are presented.  Compared to the FLU/CD8N group, the 
FLU/CD8A group showed significantly lower pulmonary resistance at 50 mg/ml MeCh (1.00 ± 
0.17 cm H2O·s/ml).  Moreover, the resistance of FLU/CD8A mice was comparable to that of 
SHAM mice (1.25 ± 0.21 cm H2O·s/ml).  In contrast, FLU/CD8N mice had higher resistance 
compared to SHAM mice, although pulmonary resistance was lower than that of the FLU mice 
(2.05 ± 0.39 vs. 4.12 ± 0.93 cm H2O·s/ml).  Interestingly, AFLU mice showed medium airway 
hyperreactivity - lower than mice infected as neonates (FLU) and higher than FLU/CD8A mice.  
Finally, adoptive transfer of adult CD8+ T cells deficient in IFN-γ prior infection 
(FLU/CD8AKO) was unable to reverse the effects on pulmonary dysfunction observed in mice 
infected with influenza as neonates (resistance at 50 mg/ml MeCh of 5.80 ± 1.83 vs. 5.17 ± 1.35 
H2O·s/ml). 
Lung histopathology was also greatly improved in the FLU/CD8A mice as compared to 
FLU, FLU/CD8N, and FLU/CD8AKO mice.  These improvements included reduced pulmonary  
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Figure 4.8  Pulmonary function, BALF cellularity and lung histopathology following 
adoptive transfer of CD8+ T cells.  Neonatal (FLU/CD8N), adult (FLU/CD8A), or adult 
IFN-γ deficient CD8+ T cells (FLU/CD8AKO) were administered one day prior to influenza 
infection of neonatal mice.  A) Pulmonary function was assayed at 30 dpi.  Mice receiving 
either adult or neonatal CD8+ T cells exhibited improved pulmonary function as demonstrated 
by a reduction in airway hyperreactivity compared to control mice infected with influenza 
(FLU), while mice receiving adult IFN-γ deficient CD8+ T cells showed no improvement in 
lung function.  Adoptive transfer of adult CD8+ T cells completely reversed airway 
hyperreactivity to SHAM levels, while FLU/CD8N mice still showed increased airway 
hyperreactivity compared to SHAM.  Data were normalized to baseline (0 mg/ml MeCh) and 
are expressed as mean ± SEM, n=4-7/group.  ***: p<0.001, compared to SHAM; #: p<0.05, 
##: p<0.01, ###: p<0.001, compared to FLU.  B) BALF cellularity.  There were less 
monocytes / AMs and lymphocytes in FLU/CD8A mice compared to FLU mice.  BALF 
cellularity for FLU/CD8N and FLU/CD8AKO mice was similar to FLU mice.  Data were 
expressed as mean ± SEM, n=4-7/group.  *: p<0.05, **:p<0.01, ***:p<0.001, compared to 
SHAM; #: p<0.05, compared to FLU mice.  C) Lung pathology was assessed at 30 dpi.  
Substantial reductions in pulmonary infiltrates are observable in the lungs of mice receiving 
adult CD8+ T cells (FLU/CD8A) prior to infection as compared to all other groups.  Other 
groups included: mice infected as neonates (FLU); mice receiving CD8+ T cells from naïve 
wild-type adults (FLU/CD8A), wild-type neonates (FLU/CD8N), or IFN-γ knockout mice 
(FLU/CD8AKO) prior to infection; and adult infected mice (AFLU).  Scale bar=100 µm. 
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inflammation (Figure 4.8.C) and mucus production (data not shown) in the infected lungs at 30 
dpi.  Adoptive transfer of adult CD8+ T cells was not able to completely reverse pulmonary 
inflammation at 30 dpi, since small foci of inflammatory cells were still observed in the 
peribronchial and perivascular areas of the lung (Figure 4.8.C).  Although the lungs from AFLU 
mice exhibited similar levels of inflammation as observed in the FLU, FLU/CD8N, and 
FLU/CD8AKO mice (Figure 4.8.C), there were no emphysematous-type lesions and little-to-no 
mucus (data not shown). 
BALF cellularity showed the same trend (Figure 4.8.B).  FLU/CD8A had less 
monocytes/AMs (18.07 ± 1.32 vs. 39.24 ± 9.35 x 104) and lymphocytes (0.37 ± 0.24 vs. 2.82 ± 
1.41) in BALF compared to FLU controls, although a significant amount of neutrophils were still 
present (10.54 ± 3.23 vs. 12.40 ± 3.61 x 104).  Conversely, transfer of neonatal CD8 + T cells 
(FLU/CD8N) or adult IFN-γ deficient CD8+ T cells (FLU/CD8AKO) prior infection did not 
reduce cellular infiltrates in BALF, as there were no differences observed between these two 
groups and FLU controls.  Interestingly, adult mice infected with influenza (AFLU) had 
significant elevated numbers of neutrophils and lymphocytes, but not monocytes/AMs, in their 
BALF compared to SHAM mice. 
The ability of neonatal mice to resolve infection following adoptive transfer of the adult 
or neonatal CD8+ T cells was then analyzed.  Viral titers were determined at 4 and 30 dpi from 
lung homogenates.  The FLU/CD8A group showed a significantly lower viral load compared to 
FLU mice (102.80± 0.040 vs. 106.42 ± 0.53 TCID50/g lung tissue).  AFLU mice also had lower viral 
titer than FLU mice (103.57± 0.18 vs. 106.42 ± 0.53 TCID50/g lung tissue).  In addition, FLU/CD8A 
mice had a significantly lower viral load than AFLU mice at 4dpi (102.80± 0.040 vs. 103.57± 0.18 
TCID50/g lung tissue).  No significant differences were observed between FLU/CD8N and FLU 
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or FLU/CD8AKO and FLU mice, although titers in both groups were slightly lower than FLU 
group (data not shown).  At 30 dpi, virus was no longer detectable in any group.  
Discussion 
In the present study, we described a neonatal mouse model of influenza A infection.  In 
this model, BALB/c mice were infected with influenza virus at 7 d of age and allowed to mature.  
The mice developed acute, severe pulmonary inflammation, which remained unresolved four 
months later and long after influenza virus was no longer detectable.  This correlated with 
significant increases in pulmonary resistance in response to increasing doses of methacholine 
(i.e., airway hyperreactivity) and decreases in compliance at four months.  Histopathologic 
analysis of the lungs from adult mice infected as neonates revealed emphysematous-type lesions 
characterized by airspace enlargement and destruction of alveolar walls.  Adoptive transfer of 
adult CD8+ T cell into the pups before infection with influenza reversed the effects of neonatal 
influenza infection as evidenced by enhanced pulmonary function (returning airway resistance to 
SHAM levels) and reduced pulmonary inflammation and reduced viral load compared to pups 
receiving neonatal CD8+ T cells.  Adoptive transfer of adult CD8+ T cells deficient in IFN-γ 
indicated that IFN-γ was critical in determining disease outcome. 
The inflammatory cells in the BALF during the acute phase (5 hpi to 10 dpi) and chronic 
phase (109 dpi) included monocytes/AMs, lymphocytes, and neutrophils.  Interestingly, although 
there were more cells in the BALF at 10 dpi than at 109 dpi (~50% more), the composition of the 
BALF was not significantly altered (i.e., both were comprised of ~80% of monocytes/AMs and 
20% of lymphocytes and neutrophils) suggesting the continued presence or secretion of 
chemokines responsible for neutrophil and lymphocyte recruitment even in the absence of 
detectable infectious virus or viral antigen.  At 109 dpi, we were unable to detect differences in 
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cytokines between mice infected as neonates and SHAM controls; however, the role of other 
cytokines or inflammatory mediators (e.g., leukotrienes, etc.) cannot be excluded.   
In addition to the chronic inflammation and airway hyperreactivity to MeCh, 
histopathologic analysis of the lungs from adult mice originally infected as neonates revealed 
emphysematous-type lesions within the lung architecture.  Intriguingly, there were no differences 
in baseline resistance between this group and SHAM controls at 109 dpi despite significant 
differences in lung architecture and inflammatory state.  The reason(s) for this are unclear, but 
may represent masking due to the persistent inflammation or a limitation of the model chosen 
(i.e., single-compartment) to measure respiratory mechanics. 
In general, the immune system of a neonate is quite different from that of an adult, in that 
the innate and adaptive immune responses are immature (Billingham et al., 1953; Bona, 2005).  
Naïve, neonatal T cells are also functionally distinct from adult T cells (Adkins, 1999); and 
effector, neonatal T cells are less able  to lyse antigen bearing cells or produce cytokines 
(Granberg et al., 1979).  Although neonatal T cells are able to mount comparable proliferative 
responses to mitogens (Yarchoan and Nelson, 1983), they have intrinsically lower levels of 
CD3/TCR, adhesion molecules, and costimulatory molecules (Velilla et al., 2006).  Data from 
our studies indicate that recruitment of T cells is different in the infected neonates versus the 
adult and although both T cell populations are induced in the neonate, CD8+ T cell numbers are 
doubled in the adults.  This suggested that cell number alone may have been responsible for the 
pathophysiological impact of neonatal influenza infection.  Although adoptive transfer of 
neonatal CD8+ T cells prior to infection did help to control the infection (i.e., reduced viral load 
and improved pulmonary function compared to neonates infected with influenza); it was not as 
effective as adoptive transfer of adult CD8+ T cells (i.e., further reduction in viral load and 
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pulmonary function equivalent to that of SHAM).  These data suggest that neonatal CD8+ T cells 
are functional impaired compared to adult CD8+ T cells.  
In addition to the lower magnitude of the T cell response in the neonates, the number of 
IFN-γ+ CD8+ T cells was significantly lower than that of their adult counterparts after influenza 
infection.  Previous studies have showed that IFN-γ plays an important role in recovery from 
influenza infection by helping to clear the virus (Bruder et al., 2006; Moskophidis and Kioussis, 
1998) and that adoptive transfer of Tc1 cells (IFN-γhi cytotoxic T cells) promotes clearance of 
the influenza virus, while transfer of Tc2 cells (IFN-γlo cytotoxic T cells) does not affect viral 
clearance (Wiley et al., 2001).  Our data confirmed that IFN-γ produced by CD8+ T cells was 
important to effectively clear influenza from the neonatal lung, since mice receiving IFN-γ 
deficient adult CD8+ T cells showed higher viral loads than mice receiving wild-type adult 
CD8+ T cells.  Moreover, adoptive transfer of IFN-γ deficient CD8+ T cells totally abolished the 
benefits observed upon administration of adult CD8+ T cells, as demonstrated by increased 
airway hyperreactivity, BALF cellularity, and lung histopathology (similar to neonatal infection 
controls).  In total, our data further demonstrate the importance of IFN-γ in the resolution of 
infection and inflammation initiated upon infection of neonatal mice.   
Viral load and immune function are inescapably linked.  Also, it is readily apparent that 
CD8+ T cells do not directly affect disease outcome and that they alter the course of 
pathogenesis by acting against virus-infected cells (i.e., decreasing viral load) through production 
of IFN-γ.  This contention is strengthened by our observation that introduction of poorly 
functional neonatal CD8 T-cells does not ameliorate disease, or act against virus-infected cells, 
thereby permitting a higher viral load in the host.  Mice receiving wild-type adult CD8+ T cells 
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exhibited lower viral loads, improved pulmonary function, a reduction in total BALF cellularity, 
and a reduction in pulmonary inflammation compared to mice infected as adults. 
Influenza and another common respiratory virus, RSV, infect the same human population 
(infants) but elicit different pulmonary diseases.  It has been reported that Th2 (IL-4+ T helper 
cells) responses dominate in neonatal immunity; while Th1 (IFN-γ+ T helper cells) responses 
dominate in adults (Adkins et al., 2000; Adkins et al., 1996; Adkins et al., 1993; Min et al., 1998; 
Pack et al., 2001).  However, studies from our lab and other groups clearly demonstrate that the 
immune response initiated by neonates is more complex (You et al., 2006).  A previous study 
showed that RSV infected neonatal mice mount a Th2 biased response when rechallenged as 
adults with RSV (Culley et al., 2002).  Although a mixture of Th1 and Th2 cells is elicited in 
lungs during reinfection, there were significantly more (4 fold) Th2 cells in lungs compared to 
mice primarily infected as adults (Culley et al., 2002).  Data from our lab showed that even at 
primary infection, neonatal RSV infection mounts a Th2-skewed response (You et al., 2006) 
compared to influenza infection (data presented here).  In fact, both infections mount a mixed 
Th1/Th2 response.  Following influenza infection about 5 fold more Th1 cells than Th2 cells 
were recruited to the lungs, while RSV infection recruited similar numbers of Th1 and Th2 cells.  
These data suggest that the immune response initiated in neonates is not predestined toward a 
Th2 response, as previously implied, and appears to depend on the antigen encountered.  Besides 
the differences in responses of helper T cells to RSV and influenza, both viruses induce a weak 
CD8+ T cell response similar in magnitude and function.  Finally during neonatal RSV 
infections, although airway remodeling is present (i.e., increased basement membrane thickness, 
smooth muscle hypertrophy, subepithelial fibrosis), there is relatively no tissue destruction (You 
et al., 2006).  In contrast, neonates infected with influenza exhibited a tremendous amount of 
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tissue destruction, which may be the principal determinant of the severity of airway symptoms.  
Taken together, there is similarity and disparity in the immune responses induced by RSV and 
influenza, and the immune and cytopathic differences may explain the specific pulmonary 
diseases elicited by these two viruses. 
In summary, our data demonstrate that infection of newborn mice with influenza has 
long-term consequences for the host inducing diffuse emphysematous changes in the lung and 
marked pulmonary inflammation.  These alterations were persistent and associated with 
increased airway resistance and reduced compliance.  The adaptive T cell response was markedly 
reduced in the neonates, with the most striking difference being observed among the CD8+ T cell 
population.  Our adoptive transfer data suggest that the immaturity of this cell population is an 
important factor in determining disease outcome in the context of the pulmonary 
microenvironment.  These data, along with recent data suggesting that one lung infection has the 
potential to modify immunity for extended periods of time (Didierlaurent et al., 2008), 
emphasize the importance of delaying the time of initial influenza infection, and therefore the 
importance of vaccination in infants and young children.  Future studies to elucidate the 
molecular mechanisms responsible for the persistent inflammation and structural alterations 
observed with neonatal influenza infection should identify important therapeutic targets capable 
of controlling long-term complications due to viral bronchiolitis in infancy.  Our observations 
(i.e., that CD8+ T cell responses in neonate are functional different than that of adults) have 
significant implications for human infants beyond just influenza infection including infant 
responses to nosocomial infections and even responses to vaccination.   
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GENERAL DISCUSSION 
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Respiratory viral infections continue to be a significant cause of morbidity and mortality 
worldwide.  Respiratory syncytial virus and influenza virus are the two major causes of lower 
respiratory tract infections (LRTI) in infants and children (Denny, 1995), and disease severity is 
inversely related to age at infection (Welliver, 2003).  In particular, infants under two years of 
age, especially those younger than six months of age, develop severe LRTI involving bronchi, 
bronchioles, and alveoli (Welliver, 2003). 
Despite the intense research on RSV and influenza, the pathogenesis of these two viruses 
is unclear, partly due to the usage of age-unmatched animal models.  The majority of the studies 
on the pathogenesis of RSV and influenza are carried out in adult mouse models.  However, 
discrepancies between pathogenesis in adult mouse models and in human infants have been 
observed.  RSV infections in infants are usually Th2 biased (Roman et al., 1997), while RSV 
infections in adult mice are Th1 biased (Peebles et al., 2001).  Influenza infections in infants 
exhibit a lack of adaptive immune responses (Welliver et al., 2007), while influenza infections in 
adult mice induce a substantial number of adaptive immune cells (Allan et al., 1990).  The 
inconsistency of immune responses between human and mouse infections indicate that an age-
matched mouse model must be used to match the maturity of immune systems in both organisms. 
Therefore, we established two neonatal mouse models of RSV and influenza infection in 
the research for the present dissertation.  In our models, both viruses led to long-term pulmonary 
dysfunction; however, the mechanisms behind this phenomenon were quite different.  The 
following discussion will detail the relevance of these two models to infections in human infants 
and the similarities and dissimilarities between the pathogenesis of these two viruses in neonatal 
mice.  We will also propose a possible model for the pathogenesis of both viruses in neonatal 
mice and discuss the implications of our study of antisense oligonucleotides (ASO) to IL-4Rα 
(Chapter 3) on the development of RSV vaccines and therapies for infants.
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Neonatal Mouse Models and Infant Infections 
Respiratory Syncytial Virus 
In our neonatal mouse model, infection with RSV at seven day of age elicited a long-term 
airway hyperreactivity associated with unresolved pulmonary inflammation, goblet cell 
hyperplasia, and airway remodeling.  In combination with an allergic model (ovalbumin), we 
demonstrated that neonatal RSV infection exacerbated many symptoms observed in allergic 
asthma including airway hyperreactivity and eosinophilic pulmonary inflammation.  These data 
mimic epidemiologic data demonstrating that infantile RSV infections correlate with long-term 
pulmonary function abnormalities and increased risk of developing recurrent wheezing and 
asthma in later life (Castro-Rodriguez et al., 1999; Hall et al., 1984; Korppi et al., 2004; Sigurs et 
al., 2000; Sigurs et al., 2005; Stein et al., 1999).  Although the duration of pulmonary 
dysfunction (i.e., 13 to 20 years) due to RSV infections during infancy is controversial, it is 
generally well accepted that severe RSV infection does induce long-term pulmonary dysfunction 
and increased sensitivity to aeroallergens.   
In humans, the question remains: does severe RSV infection during infancy predispose to 
long-term pulmonary function abnormalities or does it unmask some genetic or pulmonary 
abnormalities that may already exist?  In our neonatal mouse model, RSV infection appears to be 
an independent cause inducing persistent pulmonary dysfunction and exacerbating allergic 
pulmonary diseases well into adulthood.   
To better address this issue in humans, clinical studies using interventions such as anti-
viral drugs (i.e., ribavirin) and RSV antibodies (i.e., RSV-IGIV and palivizumab) have been 
carried out.  Current data suggest that ribavirin therapy does not protect against long-term 
pulmonary dysfunction in infants following RSV LRTI (Krilov et al., 1997; Long et al., 1997; 
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Lugo and Nahata, 1993; Rodriguez et al., 1999), which may be explained by the controversial 
effects of ribavirin on treating RSV (Ventre and Randolph, 2007), whereas clinical studies with 
RSV-IGIV suggest that a cause-effect relationship exists between RSV LRTI and the subsequent 
development of asthma.  In these studies, using RSV-IGIV in infants to prevent LRTI caused by 
RSV decreases the incidence of asthma five to nine years after treatment (Simoes, 2001).   
Interestingly, mice originally infected with RSV as neonates and then reinfected as adults 
developed Th2-biased immune responses, including pulmonary eosinophilia and IL-13-mediated 
mucus hyperproduction.  It is difficult to know what responses occur in humans upon reinfection 
because: 1) only 25 to 40% of infected infants develop severe LRTI (Collins and Graham, 2008); 
2) of those, only 40% develop long-term wheeze or asthma (Sigurs et al., 2005); and 3) recurrent 
infections can occur throughout life (Hall et al., 1991; Scott et al., 2006).  However, the tragic 
formalin-inactivated-RSV vaccine trial of the late 1960s suggests that a similar Th2-biased 
response occurred when the vaccinated infants later became naturally reinfected.  In fact, 80% of 
those vaccinated infants developed severe bronchiolitis and/or pneumonia.  Two of the 
vaccinated infants died, and the postmortem examinations revealed significant pulmonary 
eosinophilia in their lungs (Kim et al., 1969). 
Influenza 
In our neonatal mouse model of influenza, infection of seven-day-old mice induced 
persistent pulmonary pathophysiology, including airway hyperreactivity, emphysematous-type 
lesions, and severe pulmonary inflammation with alveolitis and consolidation.  Few studies have 
investigated long-term effects of influenza infection in infants, probably because it occurs less 
frequently.  However, an in-depth literature search revealed that these studies, although old, 
exist.  The data suggest that influenza infection in infants causes chronic (2.5 to 5 years post-
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infection) pulmonary dysfunction, and therefore the long-term effects of infantile influenza 
infection may be underestimated (Laraya-Cuasay et al., 1977).  
Many components of our model mimic the responses in influenza-induced LRTI in 
human infants, including influx of neutrophils and mononuclear cells into the airways, necrosis 
of epithelial cells, and alveolar edema.  More importantly, deficient adaptive immunity to 
influenza infection in neonatal mice is also consistent with that in human infants.  Limited CD4+ 
and CD8+ T cell responses are observed in fatal infantile infections of influenza (Welliver et al., 
2007).  Repeated infection in humans with the same strain is usually asymptomatic; antigenically 
similar but different strains are a frequent cause of reinfection and manifest similar symptoms as 
primary infection (Sonoguchi et al., 1986).  It would be interesting to assess reinfection with 
influenza in our neonatal mouse model to investigate whether reinfection with the same strain is 
similar to that observed in humans.  We expect prior neonatal infection would be protective 
against subsequent infection but, as with RSV memory, that protection may be incomplete due to 
early exposure to the virus (Lawrence and Vorderstrasse, 2004).  For all these reasons, neonatal 
mice provide a good model to study the immunological aspects of influenza infection in infants. 
RSV versus Influenza in Neonatal Mice 
Similarities between RSV and influenza infections in neonatal mice are obvious.  Both 
neonatal infections led to long-term airway hyperreactivity, along with persistent pulmonary 
inflammation and goblet cell hyperplasia in matured adults.  However, the magnitude of these 
responses was quite different, with influenza inducing more severe pulmonary dysfunction and 
inflammation.  Furthermore, lung injury following neonatal influenza infection was more 
prominent.  Emphysematous-type lesions were readily apparent in influenza-infected lungs, 
while RSV infection in neonates led to extensive subepithelial fibrosis (i.e., airway remodeling). 
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Cellular inflammation in the BALF during the acute phase of the infection (during active 
infection) was also more prominent in influenza infection in terms of scale.  Both viruses led to 
the recruitment of neutrophils, monocytes/alveolar macrophages (AMs), and lymphocytes; 
however, two-fold more cells were present in the BALFs of influenza-infected mice.  In addition, 
the composition of the inflammatory cells in the convalescent phase (months after virus was no 
longer detectable) was different between RSV and influenza infections: monocytes or AMs were 
the major cells observed in RSV-infected lungs, whereas neutrophils and lymphocytes comprised 
a significant portion of the inflammatory cells observed in influenza-infected lungs.  The 
difference between neonatal RSV and influenza infections, in this respect, may be attributed to 
the fact that RSV is less virulent than influenza in mice.  RSV infects mice less efficiently than 
influenza and requires 20,000-fold more infectious virions than influenza to elicit a productive 
infection compared to influenza.   
Furthermore, the time course and the amount of cytokine production in the BALF were 
quite different for RSV and influenza infections.  Influenza infection induced more robust 
cytokine responses than RSV, with the exception of higher levels of TNF-α, IL-13, and IL-17 
secreted in RSV-infected lungs.  The proinflammatory cytokine TNF-α was secreted and peaked 
as early as five hours post-infection in both RSV and influenza and was undetectable ten days 
post-infection (dpi).  Another proinflammatory cytokine, IL-6, was a bit different.  It peaked 
within five hours of RSV infection and was no longer detectable 24 hours after infection.  With 
influenza, IL-6 peaked four dpi and was undetectable six days later.  The Th2 cytokine IL-13 
peaked within 24 hours of both infections, with RSV inducing two-fold IL-13 secretion over 
influenza.  As expected, the Th1 cytokines IFN-γ and IL-12 were much higher in influenza 
infection and were barely detected in the BALF of neonates infected with RSV. 
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T cell responses in neonatal RSV and influenza infections also showed similarities and 
dissimilarities.  RSV infection in neonatal mice elicited a Th2-biased response (1:1 ratio of 
Th1/Th2 cells in the lungs) compared to influenza infection (5:1 ratio of Th1/Th2 cells).  
Responses of cytotoxic T cells (CTLs) were similar between RSV and influenza with both 
infections eliciting prominent Tc1 (IFN-γ-producing CTL) responses.  Interestingly, the 
magnitude of T cell responses in both infections was weaker than the magnitude of T cell 
responses observed in adult infections. 
Current Model for the Pathogenesis of RSV and Influenza 
Combining data from our neonatal infection studies, we propose a model for the 
pathogenesis of RSV and influenza infections (Figure 5.1).  For ease of discussion, unless 
otherwise stated, “primary infection” here means infection in neonates, and “reinfection” means 
infection in adults who had originally been infected as neonates. 
The outcome of primary infection is determined by the virulence of the invading viruses, 
the infectious doses, and the state of the host’s immunity.  Epithelial cells of the airways are the 
major targets for both viruses.  The replication of viruses in epithelial cells leads to two 
consequences: 1) the necrosis of epithelial cells and 2) the release of a series of inflammatory 
signals.  Destruction of the epithelial layer is more prominent in influenza infection, probably 
due to the fact that influenza is more virulent than RSV and replicates more efficiently in mice.  
Combined with the weak adaptive immune responses in neonates, the control of influenza 
infection is poor.  The cytopathic effects of the virus, therefore, play major roles in the 
pathogenesis of influenza infection.  In the case of RSV primary infection, both the cytopathic 
effects of the virus and the Th2-biased immune responses are responsible for the pathogenesis.  
However, since RSV is less virulent, the pulmonary disease is less severe.   
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Figure 5.1  A proposed model for the pathogenesis of primary infections of RSV and 
influenza in neonatal mice.  Both RSV and influenza infections in neonatal mice result in the 
necrosis of epithelial cells and the recruitment of inflammatory cells into the lung.  
Inflammation and destruction of the epithelial layer is more prominent in influenza infection, 
while RSV induces more Th2 cells to the lung. 
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The second consequence of viral replication in epithelial cells (i.e., the release of 
inflammatory signals) comes to the forefront when adult mice are infected.  In general, 
pulmonary disease induced by these two viruses is milder in adults than in neonates, most likely 
due to a more mature and efficient adaptive immune system and response.  However, it is 
possible that the benefit of the adult immune response could be overcome with a higher 
infectious dose.  A higher infectious dose would result in more replication of the virus and, 
subsequently, greater destruction of epithelial cells, with considerable release of inflammatory 
signals.  Large numbers of inflammatory cells, including cytotoxic T cells, are recruited to the 
infected area and exert their killing function on infected epithelial cells.  However, the bystander 
cytotoxicity of immune cells adds more destructive burden to the infected animals and is 
therefore more pathogenic than protective.  
In the case of reinfection, the pathogenesis of RSV and influenza infections differs 
drastically.  Although not tested in this dissertation research, reinfection with influenza is 
thought to be consistent with the canonical model of reinfection, based on the adult infection data 
from other groups (Lawrence and Vorderstrasse, 2004): memory of adaptive immunity is 
established during primary infection and protects the host during secondary infection.  In RSV 
reinfection, Th2-biased immune responses play major roles in the pathogenesis of secondary 
infection.  Abundant inflammatory cells, including CTLs, are recruited to the infected area to 
clear the virus; however, other recruited cells, e.g., eosinophils and Th2 cytokines, such as IL-5 
and IL-13, erroneously add inflammatory burden to the lungs and airways, and induce mucus 
hyperproduction and airway hyperresponsiveness, which are hall marks of RSV-induced illness.  
This discrepancy between RSV and influenza reinfections is possibly due to undefined molecular 
mechanisms by which RSV induces a Th2-biased memory response in neonates.  IL-4Rα is a 
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candidate for study, since this molecule has been shown to regulate selective apoptosis of Th1 
cells, leaving Th2-biased responses upon rechallenge with the same antigen (Li et al., 2004).  
Toll-like receptors (TLRs) are other good candidates, since they are at the first line of defense 
against viruses, and the interplay between these receptors and the invading virus in innate cells 
signals the down-stream adaptive immune responses, including T cell responses. 
In summary, both the cytopathic effects of the virus and immunopathology play roles in 
the pathogenesis of primary infections with RSV and influenza in mice; Th2-dominated memory 
responses contribute to the exacerbated respiratory distress upon RSV reinfection.   
There Is Hope 
The fact that no vaccines are available for RSV infection is disappointing given the 
burden of this virus in infants and the long-term effects of severe infantile infections on 
pulmonary function in children and adolescents.  The tragic vaccine trial of the late 1960s has 
intimidated vaccinologists, and the difficulty of inducing protective immune responses in infants 
with live attenuated vaccines has hampered the progress of vaccine development.   
The usual vaccination strategy uses an attenuated virus to inoculate neonates in the hope 
of eliciting protective memory responses in a rather immature or weakened immune system.  In 
contrast, we used a wild-type virus to infect neonatal mice, along with immunomodulation at the 
time of infection.  The results, so far, are promising.  We demonstrated that treating neonates 
with ASO against IL-4Rα during primary RSV infection completely protects against the 
pulmonary dysfunction usually seen in RSV reinfection.  This protection was achieved by 
inducing a strong-enough immune response with a wild-type virus instead of an attenuated one 
and by delicately balancing between Th1 and Th2 responses with IL-4Rα ASO treatment during 
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infection.  We believe that our IL-4Rα ASO treatment offers a good opportunity for future 
therapies and vaccine development strategies. 
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